#  @BIOTECHSCANNER BIOTECH SCANNER BIOTECH SCANNER posts on X about $iova, $aqst, $vktx, aur the most. They currently have [-----] followers and [----] posts still getting attention that total [------] engagements in the last [--] hours. ### Engagements: [------] [#](/creator/twitter::1408278003109466115/interactions)  - [--] Week [---------] +8,323% - [--] Month [---------] +1,752% - [--] Months [---------] +491% - [--] Year [---------] +31% ### Mentions: [--] [#](/creator/twitter::1408278003109466115/posts_active)  - [--] Week [--] -3.50% - [--] Month [---] +5.80% - [--] Months [---] +122% - [--] Year [-----] -1.30% ### Followers: [-----] [#](/creator/twitter::1408278003109466115/followers)  - [--] Week [-----] +0.18% - [--] Month [-----] +1.40% - [--] Months [-----] +8.70% - [--] Year [-----] +12% ### CreatorRank: [---------] [#](/creator/twitter::1408278003109466115/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) [cryptocurrencies](/list/cryptocurrencies) [stocks](/list/stocks) [countries](/list/countries) [technology brands](/list/technology-brands) [automotive brands](/list/automotive-brands) [currencies](/list/currencies) [social networks](/list/social-networks) [vc firms](/list/vc-firms) [exchanges](/list/exchanges) **Social topic influence** [$iova](/topic/$iova) #5, [$aqst](/topic/$aqst) #3, [$vktx](/topic/$vktx), [aur](/topic/aur), [investment](/topic/investment), [$rklb](/topic/$rklb), [$dawn](/topic/$dawn), [dawn](/topic/dawn), [$gsrt](/topic/$gsrt), [money](/topic/money) **Top accounts mentioned or mentioned by** [@therealdansfera](/creator/undefined) [@america4life72](/creator/undefined) [@marketmacher](/creator/undefined) [@henry431171040](/creator/undefined) [@mucosalmelanoma](/creator/undefined) [@iovancebio](/creator/undefined) [@dansfera](/creator/undefined) [@firetruck5](/creator/undefined) [@cricket99238](/creator/undefined) [@thebrmola](/creator/undefined) [@hkdtweets](/creator/undefined) [@akmicic2](/creator/undefined) [@pharmdaz](/creator/undefined) [@dancingtapas](/creator/undefined) [@mrdizle](/creator/undefined) [@operationatm](/creator/undefined) [@fdetranay](/creator/undefined) [@rushing9000](/creator/undefined) [@iamn0tafanboy](/creator/undefined) [@pickledabs](/creator/undefined) **Top assets mentioned** [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Rocket Lab USA, Inc. Common Stock (RKLB)](/topic/$rklb) [Day One Biopharmaceuticals, Inc. (DAWN)](/topic/$dawn) [ARS Pharmaceuticals, Inc. (SPRY)](/topic/$spry) [Frontline Ltd. (FRO)](/topic/$fro) [Auroracoin (AUR)](/topic/$aur) [NVIDIA Corp. (NVDA)](/topic/$nvda) [Arcutis Biotherapeutics, Inc. (ARQT)](/topic/$arqt) [Eli Lilly and Company (LLY)](/topic/$lly) [Novo-Nordisk (NVO)](/topic/$nvo) [AltLayer (ALT)](/topic/$alt) [Intuitive Machines, Inc. (LUNR)](/topic/$lunr) [McKesson Corporation (MCK)](/topic/mckesson) [AstraZeneca PLC (AZN)](/topic/$azn) [Tesla, Inc. (TSLA)](/topic/tesla) [Calliditas Therapeutics AB (CALT)](/topic/$calt) [Viking Holdings Ltd (VIK)](/topic/$vik) [Fusion Pharmaceuticals Inc. (FUSN)](/topic/$fusn) [Oklo Inc. (OKLO)](/topic/$oklo) [RH (RH)](/topic/$rh) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Uber Technologies, Inc. (UBER)](/topic/uber) [Viatris Inc (VTRS)](/topic/$vtrs) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Pfizer, Inc. (PFE)](/topic/$pfe) ### Top Social Posts Top posts by engagements in the last [--] hours "$NSAV so many catalysts: NSAVDEX Exchange with IBC technology + zero gas fees negotiating with Chinese crypto mining companies to join NSAV in the USA [--] crypto trading desks LuxFi NFT partnership VirtuaBroker Governance Token. What else Well glad you asked OTCQX" [X Link](https://x.com/BIOTECHSCANNER/status/1449921777476440064) 2021-10-18T02:14Z [----] followers, [--] engagements "$NSAV+ $CUBV very exciting week ahead. Lots of accumulation in anticipation of massive news. Its coming" [X Link](https://x.com/BIOTECHSCANNER/status/1456720850942574597) 2021-11-05T20:31Z [----] followers, [--] engagements "$NSAV The 51% with BW deal is in the works. Silverbear Capital specialty is guess what MERGERS AND ACQUISITIONS. $NSAV added another project with BW to be launched on Christmas Day. First of its kind and the idiots sold. Then panic selling began. $NSAV got stronger yesterday" [X Link](https://x.com/BIOTECHSCANNER/status/1460974828194828290) 2021-11-17T14:15Z [----] followers, [--] engagements "$NSAV if you dont believe the company will do what it said it will do then sell. As for me $NSAV will get it done. Mergers and acquisitions take time to complete. You only lose money if you sell for a loss. Patience will win out here" [X Link](https://x.com/BIOTECHSCANNER/status/1461734873413083139) 2021-11-19T16:35Z [----] followers, [--] engagements "January will be a very pivotal month for $NSAV. BW (51% acquisition) Vagabond (50%) Technicorum (5%) Metaverse Network partnership. Nirvana Meta partnership. OTC trading desks. Potential centralized exchanges (2). Very exciting. http://NSAVDEX.ORG http://NSAVDEX.IO http://NSAVDEX.ORG http://NSAVDEX.IO" [X Link](https://x.com/BIOTECHSCANNER/status/1479115179849760771) 2022-01-06T15:38Z [----] followers, [--] engagements "$NSAV - If you are looking to invest in the crypto/Metaverse/NFT/Mining industry $NSAV has the entire ecosystem. Their Centralized Exchange is undergoing TestFlight and in the process of applying for a license in the Philippines. [--] DEXes and crypto trading desks. Lots coming" [X Link](https://x.com/BIOTECHSCANNER/status/1506634443028639752) 2022-03-23T14:10Z [----] followers, [--] engagements "$NSAV - Besides having its own decentralized exchanges Centralized Exchange (in Test Flight) Crypto Trading Desks now crypto mining to the USA (soon) to the masses #REVENUE. https://www.stocktitan.net/news/NSAV/nsav-announces-launch-of-hive-the-first-blockchain-home-mining-guncxa8k72j0.html https://www.stocktitan.net/news/NSAV/nsav-announces-launch-of-hive-the-first-blockchain-home-mining-guncxa8k72j0.html" [X Link](https://x.com/BIOTECHSCANNER/status/1506994535041277966) 2022-03-24T14:01Z [----] followers, [--] engagements "$NSAV - Paper hands sold: [--] DEX CEX (coming 4/8) OTC trading desks NFT Market place HIVE crypto mining Technicorum +Influencio 50% Vagabond Uncharted collaboration (PR coming)share buyback AWallet managed by Silverbear Capital in HK with expertise in all things crypto" [X Link](https://x.com/BIOTECHSCANNER/status/1509658643536429056) 2022-03-31T22:27Z [----] followers, [--] engagements "$NSAV continues to add acquisitions and partnerships because its a holdings company. However its core business revolves around exchanges (crypto trading desks [--] DEX exchanges CEX NFT market place). Its Coinbase +more in its infancy. Patience my friends. Our time will come" [X Link](https://x.com/BIOTECHSCANNER/status/1517882758751739905) 2022-04-23T15:07Z [----] followers, [--] engagements "$NSAV - Disruptive market (DEX CEX NFT Crypto mining Crypto wallet Crypto trading desks GameFi SocioFi Coins Tokens Cybersecurity) patience required. Since Ive been asked a lot: Buy stock in several companies that make products & services that *you* believe in. Only sell if you think their products & services are trending worse. Dont panic when the market does. This will serve you well in the long-term. Since Ive been asked a lot: Buy stock in several companies that make products & services that *you* believe in. Only sell if you think their products & services are trending worse. Dont panic" [X Link](https://x.com/BIOTECHSCANNER/status/1520769166017507329) 2022-05-01T14:16Z [----] followers, [--] engagements "$NSAV - First of several benefits from announced loyalty program. Shareholders will get the Zayda Technologies Tokens based on their share counts and length of time they are holding. Zayda Techologies is a cybersecurity company going public in [----]. https://zaydatech.website/ https://zaydatech.website/" [X Link](https://x.com/BIOTECHSCANNER/status/1522632073768546305) 2022-05-06T17:39Z [----] followers, [--] engagements "@ChairmanOtc The one who tweets about $SIMPQ first 😀" [X Link](https://x.com/BIOTECHSCANNER/status/1545556293150179334) 2022-07-08T23:51Z [----] followers, [--] engagements "$ASTA- The time will come when the realization of missing an opportunity to generate multigenerational wealth for many traders. The company has been dropping hints on every tweet and PRs. They are all there. Dont miss this rocket. It will come" [X Link](https://x.com/BIOTECHSCANNER/status/1692359732676231400) 2023-08-18T02:16Z [----] followers, [---] engagements "$ASTA - Heres another capital venture that Astra Veda Corporation is involving in. Imagine when a medical device that will help millions of people sleep better at night getting FDA approval" [X Link](https://x.com/BIOTECHSCANNER/status/1694573044356853825) 2023-08-24T04:51Z [----] followers, [---] engagements "$ASTA - You are witnessing an amazing transformation of a brutal greedy dilution scheme from previous CEO into a legitimate Nasdaq technology venture capitalist company. How many OTC companies are doing what $ASTA is attempting to do It takes guts and courage" [X Link](https://x.com/BIOTECHSCANNER/status/1707505703676457115) 2023-09-28T21:20Z [----] followers, [---] engagements "@1EyedWilly8 Take your whatever is left in the $NSAV scam and invest in a legitimate company that is going to Nasdaq. $ASTA is the one" [X Link](https://x.com/BIOTECHSCANNER/status/1711766264417251434) 2023-10-10T15:30Z [----] followers, [---] engagements "$ASTA - While 99% of other OTC companies hide from FINRA and SEC due to their deceptive share selling schemes to enrich the crooked CEOs Astra Veda Corporation brings their legal team to Wall Street to meet with regulators. Yep. $ASTA is very different. #NASDAQ" [X Link](https://x.com/BIOTECHSCANNER/status/1712122521560977674) 2023-10-11T15:06Z [----] followers, [---] engagements "For months Ive been looking for a biotech company worth sharing. This [--] has everything: [--]. Lots of cash. (No dilution) [--]. Great pipeline. [--]. Solid clinical trials [--]. Very likely buyout candidate. [--]. Massive market (tens of billions per year). Ill release this ticker Sunday" [X Link](https://x.com/Okame5208/status/1730426476850213044) 2023-12-01T03:19Z [---] followers, [---] engagements "As promised here is the biotech company: Viking Therapeutics ($VKTX). This company I believe will yield massive returns in short and long term. $376 mil cash. Low dilution risk for 4-5 years. Amazing pipeline. Solid clinical data so far. Strong buyout candidate. Heres my take" [X Link](https://x.com/Okame5208/status/1731467948047446241) 2023-12-04T00:18Z [---] followers, [---] engagements "$VKTX - on its way to all time highs soon. Wait until more positive data on NASH and weight loss come out. Analysts PT low of $25 high of $40 average of $34. This is before new positive data coming out" [X Link](https://x.com/Okame5208/status/1732066008091795848) 2023-12-05T15:54Z [---] followers, [---] engagements "$VKTX - You know about Ozempic the drug that treats Type2 diabetes + massive weight loss benefits. I took part in the launch of Ozempic. Semaglutide is the molecule name. Did you know Viking Therapeutics VK2735 has already outperformed Semaglutide in clinical trials" [X Link](https://x.com/Okame5208/status/1732455088839704598) 2023-12-06T17:40Z [---] followers, [---] engagements "Viking Therapeutics $VKTX- Has a pipeline that makes Pfizer AstraZeneca Jensen Novartis Eli Lilly Novo Nordisk drool. Will be traded in triple digits by 1H [----] IMO. Institutions have been loading up on this company as well. Huge buyout candidate" [X Link](https://x.com/Okame5208/status/1732831057630691504) 2023-12-07T18:34Z [---] followers, [---] engagements "$VKTX - Unstoppable. Still ways to go. If you understand the pipeline of Viking Therapeutics and the market potential you would understand why I think this is heading towards triple digits" [X Link](https://x.com/Okame5208/status/1733286713496146105) 2023-12-09T00:45Z [---] followers, [---] engagements "$VKTX - Always on top of the list as a buyout candidate. I dont think the board would approve a buyout unless the money is really high like $15 to $20 billion because they know how awesome the pipeline is" [X Link](https://x.com/Okame5208/status/1734712451906613441) 2023-12-12T23:10Z [---] followers, [---] engagements "@Chuck80339031 $VKTX - It will with VK [----] (GLP1+GIP agonists) for obesity and cardiovascular diseases. It already demonstrated significant LDL reduction as well as weight loss. For NASH VK2809 phase 2b has best in class data. $VKTX will own the entire market [--] Non-Alcoholic Steatohepatitis" [X Link](https://x.com/Okame5208/status/1734742895708557403) 2023-12-13T01:11Z [---] followers, [---] engagements "$VKTX - VK2735 in phase 1: Day [--] that is [--] days after last dose got up to 7.8% weight loss with 10mg dose. liver fat by 47% in Non alcoholic fatty liver disease liver fat by 59% cholesterol by 21% LDL 23% APO(B) 21%. Phase [--] (Venture) 15mg dose will be more potent" [X Link](https://x.com/Okame5208/status/1734971608492540314) 2023-12-13T16:20Z [---] followers, [---] engagements "$VKTX- has the oral formulation of VK2735 a dual GLP-1/GIP agonists currently in phase [--]. The only oral GLP-1 on the market is Rybelsus a mono agonist. Novo Nordisk made $1.7 billions in sales in [----]. VK2735 will be much better than Rybelsus because of its dual action" [X Link](https://x.com/Okame5208/status/1735051058974515411) 2023-12-13T21:36Z [---] followers, [---] engagements "$ARQT - Roflumilast Foam phase [--] clinical trial: After [--] weeks of treatment 51% of patients had complete clearance of sebboreic dermatitis. With this data its almost impossible not to grant approval for the drug. PUDFA scheduled for tomorrow 12/16/2023" [X Link](https://x.com/Okame5208/status/1735674999141274003) 2023-12-15T14:55Z [---] followers, [---] engagements "$VKTX - Should be updating on phase [--] enrollment for VK2735 the once daily (QD) oral formulation of a dual GLP1-1/GIP agonist like MOUNJARO of Eli Lilly any day now. Very exciting. Read out is 2H [----]. The once weekly (QW) injectable version already trounced Ozempic" [X Link](https://x.com/Okame5208/status/1735726849190232551) 2023-12-15T18:21Z [---] followers, [---] engagements "$VKTX- VK2735 the dual GLP-1/GIP agonists to treat Obesity metabolic endocrine cardio diseases trial data will be positive since the injectable version is already destroying Ozempic. Massive revenue potential. By far my favorite biotech this year and many years to come" [X Link](https://x.com/BIOTECHSCANNER/status/1736788671339081950) 2023-12-18T16:41Z [----] followers, [---] engagements "$IONS - CEO + others buying before PUDFA. Hmm $IONS $AZN also seeking indication for - ATTR-CM which is a systemic progressive fatal condition that leads to progressive heart failure and death within [--] years from diagnosis. Already preparing [--] launch. Approval most likely" [X Link](https://x.com/Okame5208/status/1737915807189946483) 2023-12-21T19:19Z [---] followers, [---] engagements "$VKTX - By far my favorite biotech for [----]. Amazing pipeline with Dual GLP-1/GIP for Obesity + diabetes + NASH. Huge buyout target. 10X potential easy IMO. Biotech boom ahead in [----] top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal" [X Link](https://x.com/Okame5208/status/1738359569829482824) 2023-12-23T00:43Z [---] followers, [---] engagements "Merry Christmas friends. Wishing all of you a prosperous New Year with your investments. Lets get it 🤑" [X Link](https://x.com/BIOTECHSCANNER/status/1739433598950785359) 2023-12-25T23:51Z [----] followers, [---] engagements "$FUSN - hitting [--] wk highs but dont let that scare you. This is a MAJOR buyout target. They have some of the best cancer assets on the market. I believe they will get bought out by $AZN at some point in $3-5 billion range" [X Link](https://x.com/BIOTECHSCANNER/status/1740137403031916587) 2023-12-27T22:27Z [----] followers, [---] engagements "$VKTX and $FUSN - [----] will be extremely bullish and exciting. Both are huge buyout targets" [X Link](https://x.com/BIOTECHSCANNER/status/1740776621911458301) 2023-12-29T16:47Z [----] followers, [---] engagements "$VKTX- This is [--] of the most exciting biotech companies in [----]. Q1 - Topline results for VK2735 the oral formulation of GLP-1/GIP agonists. If data is positive it will be a huge buyout target. Cant wait" [X Link](https://x.com/BIOTECHSCANNER/status/1742212995566981182) 2024-01-02T15:55Z [----] followers, [---] engagements "$VKTX - Things are getting very serious. Several new form [--] just dropped. Massive insider buys: CEO - [------] shares. CFO - [------] shares. COO - [------] shares. Plus [--] other insiders. This tells me they are about to release data for oral VK2735 a dual GLP-/GIP agonist like Mounjaro a multi billion dollar diabetes drug with massive weight loss benefits" [X Link](https://x.com/BIOTECHSCANNER/status/1743121003352359045) 2024-01-05T04:03Z [----] followers, [----] engagements "$VKTX - Yep its a great company and buyout rumors are swirling around. I am long either way" [X Link](https://x.com/BIOTECHSCANNER/status/1744811956630905070) 2024-01-09T20:02Z [----] followers, [---] engagements "$VKTX - The only oral GLP-1 drug is Rybelsus. Novo Nordisk is making billions with. Im very confident oral VK2735 will blow Rybelsus out of the water due to its dual mechanisms of action of GLP-1 and GIP which will make VK2723 1st to a massive market of obesity+diabetes. Very exciting" [X Link](https://x.com/BIOTECHSCANNER/status/1744834036999036930) 2024-01-09T21:30Z [----] followers, [----] engagements "$VKTX - If $CYTK is valued at $10 B for [--] drug for HCM that affects [------] patients in the US. How much is $VKTX worth with a pipeline of NASH obesity diabetes and rare diseases Big pharma better bring their fat wallets to talk to $VKTX" [X Link](https://x.com/Okame5208/status/1744883508210713027) 2024-01-10T00:47Z [---] followers, [----] engagements "I love @AstraZeneca Great people with live saving products. However you need a to give yourself another chance in the GLP-1 space. You can do better than a Chinese oral GLP-1. Take a look at @Viking_VKTX. You are an amazing match for each other. Lets go $VKTX $AZN" [X Link](https://x.com/BIOTECHSCANNER/status/1744914877926232179) 2024-01-10T02:51Z [----] followers, [---] engagements "$VKTX - Data for oral VK2735 is coming in Q1. My experience with this class of drugs tells me that results will be great. This is the oral version of Eli Lillys injectable Mounjaro. It will be first oral dual GLP-1/GIP agonist to a $100B obesity market" [X Link](https://x.com/BIOTECHSCANNER/status/1745470678894039331) 2024-01-11T15:40Z [----] followers, [---] engagements "How familiar am I with the GLP-1 class Sales and marketing of Victoza the first GLP-1 injectable to market. Launched Ozempic then Rybelsus. All are great GLP-1 drugs. However the newer dual agonists like Mounjaro $LLY +VK2735 of $VKTX are much more efficacious" [X Link](https://x.com/BIOTECHSCANNER/status/1745481213198971318) 2024-01-11T16:22Z [----] followers, [---] engagements "$NVO $LLY and soon $VKTX $AMGN and other pharmaceutical companies with weight loss drugs that will rival bariatric surgeries. These surgery centers will essentially be pushed out due to high costs and risks" [X Link](https://x.com/BIOTECHSCANNER/status/1745587519150796857) 2024-01-11T23:24Z [----] followers, [---] engagements "@pharmacisting Another thing about Byetta the pen is clunky drug is not great. This is why AstraZeneca gave up on it. Its a once a day injection. Now we have a once weekly and in the future may have once monthly injection. But the game changer will be $VKTX with the oral GLP-1/GIP of VK2735" [X Link](https://x.com/Okame5208/status/1745607726263075308) 2024-01-12T00:44Z [---] followers, [---] engagements "$VKTX - $PFE (Pfizer) needs $VKTX in the worst way possible. $VKTX can revive the slumping giant. $PFE would be a smart investment in acquiring $VKTX and go after two big potential segments of hot biotech areas Obesity and Nash PFE has the resources to expedite the trials and bring both drugs to the market and gain on market share in Obesity vs $LLY Obesity is a pandemic $PFE would be a smart investment in acquiring $VKTX and go after two big potential segments of hot biotech areas Obesity and Nash PFE has the resources to expedite the trials and bring both drugs to the market and gain on" [X Link](https://x.com/BIOTECHSCANNER/status/1747720658274877649) 2024-01-17T20:40Z [----] followers, [----] engagements "@omarselim VK2735 by itself is worth $7-10B. Buying the entire $VKTX company I believe would be around $18 -20B. VK2809 is a legit NASH contender. So you can figure out the PT yourself" [X Link](https://x.com/BIOTECHSCANNER/status/1747727605896187945) 2024-01-17T21:08Z [----] followers, [---] engagements "$VKTX- Viking Therapeutics has a VERY LARGE buyout target on its back. Rybelsus is the only oral GLP-1 and its a mono-agonist indicated for Type II diabetes. Novo Nordisk is making billions. $VKTX has a dual GLP-1/GIP agonist in both oral and injectable forms. While working with Novo Nordisk I got to work with Victoza Ozempic and Rybelsus. Wegovy was launched [--] months after I left the company. If there is [--] thing I know I know this class of drugs like the backs of my hands. I also know that the dual agonists like Eli Lillys Mounjaro works better than Ozempic. I am expecting the same thing" [X Link](https://x.com/BIOTECHSCANNER/status/1747805161655828763) 2024-01-18T02:16Z [----] followers, 28.1K engagements "$VKTX - VK2735 oral formulation will be first in class and a game changer if data is good. I believe it will be great. When given a choice most patients prefer pills over injections. I believe VK2735 oral will expand the market potential massively as mentioned in PR. This is a $100 billion industry. Novo Nordisk and Eli Lilly are dealing with shortages. I spoke to a former coworker at Novo Nordisk last week and he confirmed the shortages. The market could use more drugs in this class. A lot more" [X Link](https://x.com/BIOTECHSCANNER/status/1748063506891472956) 2024-01-18T19:23Z [----] followers, [----] engagements "It really depends if the buyout is just for the drug or the entire company. If the buyout is for the company if I were $VKTX I would negotiate for a higher price due to their assets in NASH with VK2809 that is doing very well in clinical trials. They also have a drug for Rare disease as well. Then you bring in VK2735 in both formulation. I would not take anything less than [--] to [--] billion for the entire company. VK2809 may be first to market and will generate billions per year for years to come. Their assets are pretty impressive. Just my opinion" [X Link](https://x.com/BIOTECHSCANNER/status/1748076310482632803) 2024-01-18T20:14Z [----] followers, [---] engagements "@semodough @Pharmdca Im glad to hear because people think Im crazy saying $VKTX has a massive target on its back for acquisition" [X Link](https://x.com/BIOTECHSCANNER/status/1748114705862853104) 2024-01-18T22:46Z [----] followers, [---] engagements "Great question and I appreciate it. Its a great company with amazing pipeline. With that comes great demands for their drugs. More than likely they dont have the manufacturing capability and a sales and marketing team yet. That will take quite a bit of time and money. However they are still early as far as the product lifecycle: VK2735 Phase 1-2 for GLP-1/GIP. VK2809 phase 2b. Therefore they still have time to get all that done. This is why I believe $VKTX wouldnt mind being acquired by $PFE or $AZN for example because all of those disadvantages will be solved instantly. I hope that answered" [X Link](https://x.com/BIOTECHSCANNER/status/1748142738388775039) 2024-01-19T00:38Z [----] followers, [---] engagements "@omarselim They have not announced. I am not surprised if they are waiting on initial data on oral VK2735. If thats positive my buyout price of $15-20 billion for the entire company is very reasonable" [X Link](https://x.com/BIOTECHSCANNER/status/1748387720529944717) 2024-01-19T16:51Z [----] followers, [---] engagements "@Carflos223Matos @omarselim Not yet but never say never. My PT for $VKTX is with or without buyout. I absolutely love the pipeline of this company. I believe the price will be high double digits by eoy. Triple digits in 3-5 years" [X Link](https://x.com/BIOTECHSCANNER/status/1748391428034535695) 2024-01-19T17:06Z [----] followers, [---] engagements "$VKTX - For the record I invested in the company because of its amazing pipeline and long term growth not because of a buyout. If a buyout happens great If not still great" [X Link](https://x.com/BIOTECHSCANNER/status/1748430056932647074) 2024-01-19T19:39Z [----] followers, [---] engagements "$VKTX I got to work with Pfizer $PFE counterparts on a respiratory product while working at Boehringer-Ingelheim Pharmaceuticals several years back. They have great manufacturing facilities and a massive sales force. If Pfizer would buy $VKTX the entire company would be revitalized and immediately becoming a contender in the diabetes obesity and NASH space. This union makes perfect sense" [X Link](https://x.com/BIOTECHSCANNER/status/1748478862000803867) 2024-01-19T22:53Z [----] followers, [----] engagements "$GPCR their GLP-1 mono agonist GSBR [----] looks ok. I believe $VKTX Dual agonist GLP-1+GIP oral VK2735 will be more potent. As a general rule the more receptors involved the better. In this case a patient taking VK2735 will be basically taking [--] gut hormones (incretins) instead of just one with GSBR [----]. In the very near future you will start seeing combinations of GLP-1+ Glucagon GLP-1 + Amylase (inside info there) GPP-1 + GIP+ Glucagon and a couple more. Mono agonist that only works with GLP-1 will not be the drug of choice. Hope that helps" [X Link](https://x.com/BIOTECHSCANNER/status/1748485960638030267) 2024-01-19T23:21Z [----] followers, [----] engagements "$VKTX - Why do I invested in Viking Therapeutics and not others within the GLP-1 space with other dual agonists like GLP-1+Glucagon and other combinations Simple. Because $VKTX - has a dual agonist - VK2735 (GLP-1+GIP) that is similar to Eli Lillys Zepbound (obesity) and Mounjaro (Type [--] diabetes). The risk is MUCH lower because the combination is already proven to be extremely effective in both obesity and Type [--] diabetes on the market. Currently that is the only GLP-1 combination available on the market. Another reason Based on phase [--] data safety+efficacy profile was excellent. $VKTX said" [X Link](https://x.com/BIOTECHSCANNER/status/1749327521651245538) 2024-01-22T07:05Z [----] followers, [----] engagements "$VKTX- VK2735 patients still achieved statistically significant weight loss on day 43; that is [--] days after their last dose. The weight loss benefit was long lasting. An important marker of sustained efficacy. Yes they have a golden egg on their hands" [X Link](https://x.com/BIOTECHSCANNER/status/1749468439150748035) 2024-01-22T16:25Z [----] followers, [----] engagements "$VKTX - Jim Cramer suggested that if $TSLA shares would continue to drop that $LLY Eli Lilly with a market cap of approximately $600 would replace Tesla as [--] of the Magnificent [--]. Tirzepatide a GLP-1/GIP dual agonist under the brand name Zepbound for obesity and Mounjaro for Type [--] is responsible for a huge part of $LLY growth. Potentially leading it to be the first pharmaceutical company to reach $1 trillion dollar market cap. In case you havent heard $VKTX has a drug called VK2735 with the same combination and mechanism of action as Zepbound and Mounjaro that has performed very well in" [X Link](https://x.com/BIOTECHSCANNER/status/1749676621420773385) 2024-01-23T06:13Z [----] followers, [----] engagements "$VKTX - People sometimes ask me if the stock will tank if the results for the oral formulation of VK2735 is not good. My answer is ask yourself: Does Eli Lilly $LLY a $600 billion pharmaceutical company making billions and billions with [--] drug -Tirzepatide in the names of Zepbound for obesity and Mounjaro for Type [--] diabetes have an oral formulation of Tirzepatide No So if injectable (subq) VK2735 is showing extremely good data so far and could even be better than Tirzepatide does it matter if the oral version of VK2735 didnt do well in clinical trials No Because $VKTX will still make" [X Link](https://x.com/BIOTECHSCANNER/status/1750075018560573859) 2024-01-24T08:36Z [----] followers, 11.8K engagements "@stevebaldwin25 @semodough I have a long term goal with $VKTX. I am an investor more than a trader. I do trade certain stocks but $VKTX is part of my long term portfolio. Not going to give pt but the sp is going much much higher than where it is today" [X Link](https://x.com/BIOTECHSCANNER/status/1750170153738711102) 2024-01-24T14:54Z [----] followers, [---] engagements "$VKTX - I always get a funny feeling on big dips because Im thinking do they know what they are selling If you want to gauge the potential for $VKTX look at $LLY and $NVO and realize that the company has a drug in clinical trials right now that is as good or better than these companies drugs. IYKYK. Thats all I can say" [X Link](https://x.com/BIOTECHSCANNER/status/1750217542197559506) 2024-01-24T18:02Z [----] followers, [---] engagements "$VKTX - I would love to be on the sales and marketing leadership team once VK2735 is approved @Viking_VKTX. Lets kick some $LLY and $NVO a$$" [X Link](https://x.com/BIOTECHSCANNER/status/1750254139068584303) 2024-01-24T20:27Z [----] followers, [---] engagements "$VKTX - tomorrow will be exactly [--] months since @Viking_VKTX reports its earnings. Its definitely not going to be tomorrow. The buyout rumors are getting louder. Could it be Or waiting on oral VK2735 data Hmm" [X Link](https://x.com/BIOTECHSCANNER/status/1750338054571573489) 2024-01-25T02:01Z [----] followers, [---] engagements "$VKTX - Another buyout rumor" [X Link](https://x.com/BIOTECHSCANNER/status/1750342761658622120) 2024-01-25T02:20Z [----] followers, [----] engagements "It depends on your goal and your entry. I am sure its pretty low on the entry. Congrats. When you first get into $VKTX what price did you have in mind. Im in the pharmaceutical industry and I get to see sales and revenues from these drugs: Victoza Rybelsus and Ozempic when I was with Novo Nordisk. What I have seen from VK2735 is $VKTX has a very good and efficacious drug that has a potential to rival Mounjaro and Zepbound. I know for certain it will destroy Ozempic and Wegovy. My goal for VKTX is pretty high. I have quite a bit more than you but at a much higher entry. Thanks for the" [X Link](https://x.com/BIOTECHSCANNER/status/1750519380868202741) 2024-01-25T14:01Z [----] followers, [---] engagements "$VKTX - VK2735 was internally developed and chosen as stated We are developing a unique series of novel dual agonists of the glucagon-like peptide [--] (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders such as obesity NASH and certain rare disorders. Our lead clinical programs drug candidate is VK2735. Data announced during the first quarter of [----] from a Phase [--] trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive" [X Link](https://x.com/BIOTECHSCANNER/status/1750656206421573978) 2024-01-25T23:05Z [----] followers, [----] engagements "$VKTX - VK2735 part [--] - Subcutaneous formulation is GLP-1 + GIP dual agonist just like Mounjaro or Zepbound from Eli Lilly. The company hasnt released the molecular structure for VK2735 yet but it will be very similar yet slightly different. GLP-1 and GIP are gut hormones that are released by the L-cell in the case of GLP-1 and K-cells for GIP after a meal. After eating a meal the blood sugar level will increase from the carbohydrates that we ate. The hormone GLP-1 will cause the beta cells in the pancreas to release insulin to make sure blood sugar level remains normal. I could go into more" [X Link](https://x.com/BIOTECHSCANNER/status/1750668201715720592) 2024-01-25T23:53Z [----] followers, [----] engagements "$VKTX -VK2735 part [--] - Oral VK2735 - This will be the first GLP-1 /GIP oral agent to market if Viking Therapeutics can get it there. This will complement the subcutaneous version really well as pointed out by the CEO Brian Lian via communications. There is only [--] oral but its a mono GLP-1 agonist Rybelsus (I also launched). Its effectiveness is not anywhere near as good as its subcutaneous version Ozempic. I expect this will be the same with VK2735 oral vs the subq version. Why Because there is a substance in the stomach called acid. And its brutal for peptides. This is why there is no oral" [X Link](https://x.com/BIOTECHSCANNER/status/1750678873665057249) 2024-01-26T00:35Z [----] followers, [----] engagements "@KVGR87 $AMGN - make sense due to his relationships with them. However Amgen has a really good obesity drug in its pipeline as well. I think he would prefer $AMGN because thats where he came from. Thanks for the suggestion" [X Link](https://x.com/BIOTECHSCANNER/status/1751095290835177594) 2024-01-27T04:10Z [----] followers, [---] engagements "$VKTX - Really cool watching this: On July [--] [----] members of the Viking Therapeutics team visited the Nasdaq MarketSite in New Yorks Times Square to ring the opening bell. There will be very happy faces like the ones you see here after the buyout. They deserve the rewards for the tireless work that they have done" [X Link](https://x.com/BIOTECHSCANNER/status/1751325021350277163) 2024-01-27T19:23Z [----] followers, [---] engagements "$VKTX - Roche bought Carmot Therapeutics Inc for $2.7b with basically [--] molecule- a GLP-1/GIP dual agonist. They also have an oral mono agonist GLP-1. The oral GLP-1 will be meh at best. Thats really about all. $VKTX - pipeline is so much more attractive and game changing potential. VK2809 for NASH looking great and waiting for [--] week biopsy confirmation. This by itself is worth more than $2.7b. Then the King Kong of obesity and diabetes and other endocrine disorders in VK2735 subcutaneous once weekly formulation. This is another at least $3b. But here is where the fun begins- Oral VK2735" [X Link](https://x.com/BIOTECHSCANNER/status/1751399155967111522) 2024-01-28T00:17Z [----] followers, [----] engagements "$VKTX- My top [--] big pharma companies that WILL acquire Viking Therapeutics: [--]. $PFE market cap $155B they can afford $10-15B easily. Recently failed on their twice a day (BID) oral GLP-1 for obesity. I think they still have not given up on the GLP-1 gold rush. [--]. $BMY market cap $101B can also afford to buy $VKTX. Bristol Myers Squibb also recently gave up on BMS-986036 for NASH. VK2809 looks pretty attractive right now. Also VK3735 shows tremendous liver fat reduction and a potential combination of VK2809 and VK2735 as briefly discussed during the Q3 [----] earnings call. Lastly $VKTX Senior" [X Link](https://x.com/BIOTECHSCANNER/status/1751478184258809963) 2024-01-28T05:31Z [----] followers, [----] engagements "$VKTX- I really like the way CEO Brian Lian describes his thoughts about complementary use case for oral and subq VK2735. He basically says dont expect oral VK2735 to attain the same efficacy as subq. This is true and always be true unless we found a way to increase bioavailability of peptides in the stomach significantly. Right now its around .4-1% with Rybelsus. Novo Nordisk co-formulated Semaglutide with Salcaprozate sodium to improve absorption. The drugs have to overcome a highly acidic environment and a mucous lining that coats the intestines so scientists have to reduce the acidity in" [X Link](https://x.com/BIOTECHSCANNER/status/1751685481916498078) 2024-01-28T19:15Z [----] followers, [----] engagements "Yes he did. This is because they are more focused than the PK (pharmacokinetic- what the body does to the drug- absorption and elimination) and some PD (pharmacodynamics - what the drug does to the body such as glucose reduction and weight loss. Phase [--] is where the focus is more on PD. He sets the expectations low and he should" [X Link](https://x.com/BIOTECHSCANNER/status/1751800977542279373) 2024-01-29T02:54Z [----] followers, [--] engagements "@Bios4L True. But remember CEO COO CFO CSO (Chief Scientist) and other high ranking officials want it too" [X Link](https://x.com/BIOTECHSCANNER/status/1752003923060109769) 2024-01-29T16:21Z [----] followers, [---] engagements "$VKTX- To invest in biotechs you have to try to think like a CEO of every company either large or small. This will help you reduce your risks as you make investments decisions. Why do I keep saying $VKTX is an infinitely better buyout target with VK2735 (GLP-1/GIP) dual receptor agonist than other companies with other GLP-1 mono or dual agonists Simple: RISKS. Known vs unknown. Exhibit A: Roche to acquire Carmot at a purchase price of $2.7 billion upfront and the potential for $400 million in milestone payments. Roche chose Carmot because of the dual receptor agonist CT-388 (GLP-1/GIP). This" [X Link](https://x.com/BIOTECHSCANNER/status/1752193096610136138) 2024-01-30T04:52Z [----] followers, [----] engagements "$VKTX - Look how much $NVO is making from Ozempic and Wegovy. These are mono GLP-1 receptor agonist. VK2735 will perform better than these. $NVO [----] revenues: -Ozempic $13.9B USD. 66% coming from US. -Wegovy $4.5B USD. 94% coming from US. These two products generated 55% of Novo's [----] revenue up from 37% in [----]. Annual report: https://t.co/WzRujiOiXt $NVO [----] revenues: -Ozempic $13.9B USD. 66% coming from US. -Wegovy $4.5B USD. 94% coming from US. These two products generated 55% of Novo's [----] revenue up from 37% in [----]. Annual report: https://t.co/WzRujiOiXt" [X Link](https://x.com/BIOTECHSCANNER/status/1752686781768609913) 2024-01-31T13:34Z [----] followers, 18.4K engagements "$VKTX - Lets talk about advantages and disadvantages between oral VK2735 and Subq form. Subq: Advantages: [--]. Unrivaled efficacy. A patient gets an instant boost of the analog incretin hormones (GLP-1 GIP) in the body. [--]. Once weekly dosing (QW) is very convenient. You can give your self an injection and go on a week vacation without having to carry the drug with you. [--]. The pain in minimal with injections. Disadvantages Subq: [--]. The needle fear is strong no matter how we spin it. [--]. Pain is minimal but it creates anxiety. [--] May require refrigeration in certain situations. [--]. If you have" [X Link](https://x.com/BIOTECHSCANNER/status/1752792750435533152) 2024-01-31T20:35Z [----] followers, [----] engagements "I would be shocked if there is ONLY [--] unidentified suitors I am kind of torn between wanting $VKTX to get bought out and for it to partner with big pharma so they could actually make money money on these drugs down the road. You saw what $NVO made on Ozempic-$13b. Thats [--] year with shortages This is why I said $15-20b price tag for the entire company. Remember $VKTX has a really good molecule VK2809 for NASH too Big pharma will make their money back in no time People think I being unreasonable but have they touched Ozempic Victoza Mounjaro Rybelsus Seeing sales numbers in meetings I have" [X Link](https://x.com/BIOTECHSCANNER/status/1752828529442517001) 2024-01-31T22:57Z [----] followers, [----] engagements "$VKTX - My expectations for oral VK2735 body weight reduction is pretty muted because I understand and accept the challenges the stomach presents to large molecules like GLP-1 or GIP. The large the molecule the harder it is to be absorbed. I can go deeper into the molecular level but not necessary. VK2735 is larger because it has is a dual receptor agonist. You may notice most companies go with a mono agonist GLP-1 instead of a dual agonist GLP-1/GIP. This is not by accident. $VKTX is going for a home run here. They already know how good the subq version is. So the risk of going for a dual" [X Link](https://x.com/BIOTECHSCANNER/status/1752871475269235063) 2024-02-01T01:48Z [----] followers, [----] engagements "$VKTX- buyout or not. VK2735 is badly needed in the market to ease the shortage. 7.8% weight loss adj. mean and 6% placebo adjusted in [--] weeks with a low and mid dose is ridiculously good. The weight loss was maintained [--] days after the last dose Now you know why the tremendous interest in the VENTURE trial: The trial was designed to enroll approximately [---] adults who are obese (BMI [--] kg/m2) or adults who are overweight (BMI [--] kg/m2) with at least one weight-related comorbid condition. Due to heightened clinician and patient interest the trial's enrollment target was increased to 176" [X Link](https://x.com/BIOTECHSCANNER/status/1753077444733476972) 2024-02-01T15:26Z [----] followers, [----] engagements "$VKTX - The most exciting part about VK2735 Phase [--] trial is the very very low side effects. Viking was smart because as I told you yesterday the side effects of this class of drugs can be really bad. Mostly nausea and vomiting. When Trulicity came out there were reports of projectile vomiting. Yep Sorry for ruining your lunch. So the 5mg and [--] mg got really good efficacy without bad side effects. This allows them to increase the high dose (10mg) by 50% to 15mg in the Phase [--] VENTURE trial. They believe VK2735 has plenty of room to achieve more efficacy without increasing too much side" [X Link](https://x.com/BIOTECHSCANNER/status/1753086680939024630) 2024-02-01T16:03Z [----] followers, [----] engagements "Thanks for sharing this. Several people have asked me about $ALT Pemvidutide a dual GLP-1/Glucagon receptor agonist versus VK2735 a dual GLP-1/GIP receptor agonist. It is not surprising that VK2735 outperforms Pemvidutide. As I stated before GLP-1/GIP is a known and proven asset on the market- Mounjaro and Zepbound (Tirzepatide) whereas GLP-1/Glucagon is still an unknown and unproven molecule. Pemvidutide looks decent and I believe will do well once approved but will always fall behind Tirzepatide and VK2735 (still waiting on VENTURE). I also mentioned previously that Roche just acquired" [X Link](https://x.com/BIOTECHSCANNER/status/1753273389882683526) 2024-02-02T04:25Z [----] followers, [--] engagements "$VKTX - Many are curious about the phase [--] VENTURE trial of VK2735 and how its going to perform. You have seen [--] solid examples of how subq dual GLP-1/GIP receptor agonist: [--] and its a big one Eli Lillys $LLY Tirzepatide (Zepbound and Mounjaro) these [--] drugs will fuel Lilly for the next [--] years or more. [--]. Carmot CT-388. [--]. VK2735 itself in its phase [--] trial with 6% weight loss placebo adjusted and adjusted mean of [---.%] in just [--] weeks is very very very good and has potential to be best in class including Tirzepatide. And they have not even used the highest dose of 15mg in the phase [--] trial" [X Link](https://x.com/BIOTECHSCANNER/status/1753439022238638282) 2024-02-02T15:23Z [----] followers, [----] engagements "$VKTX - Yes thats right. You will not be able to find a subq GLP-1/GIP dual receptor agonist performing badly in clinical trials. You should expect and anticipate great results from the phase [--] VENTURE trial with VK2735 that already giving you a glimpse of its potentially best in class results in a phase [--] trial. Its not like you have not seen anything at all. Dont let the shorts scare you. Science is on our side here" [X Link](https://x.com/BIOTECHSCANNER/status/1753458054891225334) 2024-02-02T16:39Z [----] followers, [----] engagements "VENTURE trial data for subq VK2735 is between now and end of June [----]. Oral VK2735 in between now and end of March. Earnings call is next Wednesday February [--] after market. I dont know if we are getting data on oral or subq or not. Its coming soon though. I am very excited about it" [X Link](https://x.com/BIOTECHSCANNER/status/1753463896092954798) 2024-02-02T17:02Z [----] followers, [---] engagements "$VKTX - Just a reminder Novo Nordisk $NVO Rybelsus gets about [--] lbs weight loss with 7mg and 5lbs with 14mg dose. And its making billions. Oral VK2735 I believe will easily surpass that" [X Link](https://x.com/BIOTECHSCANNER/status/1753511523308450092) 2024-02-02T20:11Z [----] followers, [----] engagements "You shouldnt worry. You should feel even more confident. The point is ALL GLP-1/GIP that have put through at least a phase [--] trial have passed with flying colors. I have not mentioned this before but you technically cannot compare trials because the participants baselines demographics are different from another. The only thing that is important is that results are somewhat close. Why Because the patients outside of clinical trials are wildly different from one another. But overall the results should be similar to what we see in clinical trials. For example if VK2735 gets 15% in the VENTURE" [X Link](https://x.com/BIOTECHSCANNER/status/1753601373680402706) 2024-02-03T02:08Z [----] followers, [---] engagements "$VKTX - Management can totally destroy shorts with potentially positive VENTURE data. Icing on the cake would be great tolerability and safety profile and 2-3% weight reduction with oral VK2735. Remember oral is still phase [--]. They can make all kinds of adjustments to it in phase [--]. I believe shorts will be trapped here. Science is on our side. Safety is on our side. Efficacy is on our side" [X Link](https://x.com/BIOTECHSCANNER/status/1754534008946323822) 2024-02-05T15:54Z [----] followers, [----] engagements "I like $VKTX molecule better just because its proven. VK2735 subq is almost identical to that of $LLY Mounjaro and Zepbound. These two drugs will eventually dominate the diabetes and obesity market. They basically are doing that already. VK2735 actually showed better results than those at [--] weeks not even with the highest dose. I believe $VKTX is about to make a huge splash in the over $100B market. If it showed best in class data in VENTURE here soon you me and the rest of us longs are going to be very happy. I think VENTURE will show best in class data or close to it" [X Link](https://x.com/BIOTECHSCANNER/status/1754548427466100851) 2024-02-05T16:51Z [----] followers, [---] engagements "$VKTX - WARNING ⛔ to shorts. Get out while you can. You are basically shorting a proven asset (GLP-1/GIP dual receptor agonist). Look no further than Mounjaro and Zepbound. VK2735 is almost the same drug that has shown to be even better at [--] weeks in phase [--]. Now in phase [--] with a longer duration and a higher dose. Again you are going to get destroyed. Be smart" [X Link](https://x.com/BIOTECHSCANNER/status/1754591168942178453) 2024-02-05T19:41Z [----] followers, [----] engagements "$VKTX- This is why I think shorts are trapped. Its a lose - lose situation if data is great which I am very confident that it will be. This person brought up this issue which plays right into what many shareholders management and staff at $VKTX are hoping for a buyout. If not then a partnership. Either way $VKTX will absolutely fly. The very fact that $VKTX doesnt have a manufacturing facility is the reason why its on everyones top merger and acquisition list Shorts are trapped. @BIOTECHSCANNER even if successful the operational challenge of manufacture at scale will render the product a" [X Link](https://x.com/BIOTECHSCANNER/status/1754605121239916605) 2024-02-05T20:37Z [----] followers, [----] engagements "$VKTX- I love a biotech startup with a great pipeline and no manufacturing plant. A perfect recipe for a buyout or partnership with big pharma. Shorts are in serious trouble. Deservedly so. Leerink $VKTX Management previously noted that external business development interest in their obesity program remains high along with several discussions centered on the companys NASH program- earnings 2/7 will be closely watched Leerink $VKTX Management previously noted that external business development interest in their obesity program remains high along with several discussions centered on the" [X Link](https://x.com/BIOTECHSCANNER/status/1754642587074637898) 2024-02-05T23:06Z [----] followers, [----] engagements "Thanks for your input. Totally agree with you. This is why I have been pounding the table on $VKTX is the fact that their drug VK2735 is kind of already on the market $LLY Mounjaro and Zepbound did all the trail blazing for the GLP-1/GPI dual agonists. Now all $VKTX has to do is to match or out match them in VENTURE. This is regardless of the oral. They will make tens of billions on the subq alone. However I think CEO wants the oral VK2735 to do well slso so he can get a bigger yacht after buyout. There is no way that $VKTX is not getting bought out" [X Link](https://x.com/BIOTECHSCANNER/status/1754708477358829744) 2024-02-06T03:27Z [----] followers, [----] engagements "$VKTX - I appreciate those of you sharing your knowledge because I believe education is highly lacking for biotech investors. We can help each other to be wiser investors and not flippers. So why do you think I keep bringing up Eli Lilly $LLY Mounjaro and Zepbound when I talk about $VKTX and its lead molecule for obesity VK2735 In the medical profession and the pharmaceutical industry there is a very widely known and accepted concept called CLASS EFFECT. Those who dont know you definitely should find out before you invest another penny in any biotech" [X Link](https://x.com/BIOTECHSCANNER/status/1754845493601960156) 2024-02-06T12:32Z [----] followers, [----] engagements "Friends please listen to me about this: Do not pay to join these Discord servers so they can pre-load and dump on you. They pump these sub $1 biotechs with flow floats. You will destroy your account. They are not qualified to talk biotechs. They will make up random catalysts to tempt you. Be smart with your hard earned money. When I call out a ticker it will be a medium to long swing. It takes weeks for me to get a full position. Chances are your average will be lower than mine. Many of my tickers will have multiple catalysts and can take months to a couple of years to play out. Also I may" [X Link](https://x.com/BIOTECHSCANNER/status/1756367523761512708) 2024-02-10T17:20Z [----] followers, 10.7K engagements "@FatManApe I see it heading back at least 3x where it is now because the momentum of their pipeline will accelerate. Also buyout possibilities as well. They basically will have a monopoly in TIL for several types of solid tumors" [X Link](https://x.com/BIOTECHSCANNER/status/1757545579356271084) 2024-02-13T23:21Z [----] followers, [---] engagements "$IOVA- Latest 13Gs show institutions like Vanguard Blackrock and others added more than [--] million shares. You think they know whats coming" [X Link](https://x.com/BIOTECHSCANNER/status/1757628654878666971) 2024-02-14T04:51Z [----] followers, [----] engagements "In the spirit of following the science I took a position in $LUNR. I have traded this ticker several times. Its at near absolute bottom. They have a launch tonight at 1:05 am EST. They have contracts with NASA to bring scientific instruments to conduct various tests. I will provide more DD later. On 2/22/2023 share price went up to $136. It wont go that high but if they successfully landed on the moon. You know where the price will be Watch the launch live tonight" [X Link](https://x.com/BIOTECHSCANNER/status/1757928224820982216) 2024-02-15T00:42Z [----] followers, [----] engagements "$LUNR - As humans have aspirations to explore deeper into space and beyond Intuitive Machines will be in the thick of it all. The company if successful with its lander being carried by SpaceX Falcon [--] tonight its market cap will be in billions again. It all starts tonight" [X Link](https://x.com/BIOTECHSCANNER/status/1757933864352198675) 2024-02-15T01:04Z [----] followers, [----] engagements "$LUNR - Launch time is 12:20 am EST" [X Link](https://x.com/BIOTECHSCANNER/status/1757965888609731039) 2024-02-15T03:11Z [----] followers, [----] engagements "$LUNR LIVE broadcast of launch" [X Link](https://x.com/BIOTECHSCANNER/status/1757998985787080775) 2024-02-15T05:23Z [----] followers, [----] engagements "$LUNR - Loving the journey to the moon in every sense of the word. 🚀" [X Link](https://x.com/BIOTECHSCANNER/status/1758143504666989001) 2024-02-15T14:57Z [----] followers, [---] engagements "@garyhead70 Probably not. They will negotiate of course" [X Link](https://x.com/BIOTECHSCANNER/status/1758617408112120114) 2024-02-16T22:20Z [----] followers, [---] engagements "@West0_Cap @KerrisdaleCap They were completely wrong in their report. I saw the 20% drop and was hoping the Chief Scientific Officer of $ALT would counter but nothing. Heartbreaking" [X Link](https://x.com/BIOTECHSCANNER/status/1759378201816473853) 2024-02-19T00:43Z [----] followers, [---] engagements "$ALT -Did you know that I also spent months researching $ALT I almost picked $ALT over $VKTX. I think for now I chose wisely. However if you have invested in $ALT I believe the phase [--] will not bomb like @KerrisdaleCap wrongly predicted (for selfish reasons). I believe $ALT phase [--] results will be great" [X Link](https://x.com/BIOTECHSCANNER/status/1759383831423914051) 2024-02-19T01:06Z [----] followers, [----] engagements "$ALT - Please listen to me - Nausea vomiting and diarrhea are the [--] most common adverse events and mainly mild to moderate and occur mostly in the first [--] weeks. Did you know that there is a drug on the market right now that can produce projectile vomiting Its Trulicity. Its the once weekly GLP-1 that belongs to drum roll please- Eli Lilly. Its making billions. The three adverse events are universally acknowledged and accepted. If you take these drugs and experience no nausea it is not going to work. But doctors know how to manage nausea. THE BENEFITS OUTWEIGH SIDE EFFECTS. And the side" [X Link](https://x.com/BIOTECHSCANNER/status/1759401949416374406) 2024-02-19T02:18Z [----] followers, [----] engagements "$ALT @KerrisdaleCap pemvidutide didnt do much for glucose control. This is the same mistake the last idiot wrote about $ALT (coincidence) from Seeking Alpha. Free lesson here. This is an obesity not diabetes trial. So the glucose level must be outside of the diabetic range. Thats why the baseline is [---]. If pemvidutide lowered glucose in this trial patients would have gone hypo and possibly died" [X Link](https://x.com/BIOTECHSCANNER/status/1759406857339252942) 2024-02-19T02:37Z [----] followers, [----] engagements "Folks we are a long way away from obesity being a crowded market. $VKTX $NVO $LLY $ALT are not competing against each other yet. Obesity is a big (pun intended) market. They are competing against a costly disease- obesity" [X Link](https://x.com/BIOTECHSCANNER/status/1759410140871008477) 2024-02-19T02:50Z [----] followers, [----] engagements "$ALT $VKTX The point I am trying to get across is this: [--]. Obesity is a worldwide problem [--]. Obesity and its consequences overburden the worlds healthcare systems. [--]. We need better treatments to fight diabetes and obesity. [--]. We still dont know what combination will work best yet even though there are at least [--] different combinations coming out including gene manipulation. [--]. We still need more drugs to combat [--]. THE MARKET IS NOT CROWDED YET [--]. No companies is trying to overthrow $LLY and $NVO please stop using this ridiculous argument. [--]. We should cheer for companies to succeed. The more" [X Link](https://x.com/BIOTECHSCANNER/status/1759461583741137027) 2024-02-19T06:15Z [----] followers, [----] engagements "You should be wary of a person defending a ticker that he or she is not in. What the heck is integrity doing on social media Be wary of someone that stands up for something on social media. Its really strange. $ALT must be the ticker I am heavily in since I am spending so much time defending it right I dont have any $ALT shares. I will not invest in $ALT. Not because it will fail but its because I like $VKTX better based on my qualifications. Yes Jim. Dont trust anyone including me" [X Link](https://x.com/BIOTECHSCANNER/status/1759466908057805120) 2024-02-19T06:36Z [----] followers, [--] engagements "@fluffer9 😂 You afraid of $ALT You know $VKTX are going for the same diseases right Obesity and NASH. So when I looked into the hot market for obesity you would think its natural for me to look at both of them right" [X Link](https://x.com/BIOTECHSCANNER/status/1759468708370526375) 2024-02-19T06:43Z [----] followers, [---] engagements "@fluffer9 $VKTX You know I almost blocked you because I thought you were trying to bash $VKTX a while back when you asked me about patents issues with the drugs that VKTX owns. Now youre accusing me of selling $VKTX for $ALT Really 😂" [X Link](https://x.com/BIOTECHSCANNER/status/1759470342169305529) 2024-02-19T06:49Z [----] followers, [----] engagements "You know $ALT and $VKTX are both dual agonists right They target different receptors. I already mentioned $LlY is coming out with the triple agonist and is showing effectiveness. The reason I invested in $VKTX and not $ALT is because it is less risky thanks to Mounjaro and Zepbound. The bottom line is we dont know how $ALT will turn out. I just happen to think it will be fine. The thing that got me started on this was Krissdale said the drug did nothing for glucose control" [X Link](https://x.com/BIOTECHSCANNER/status/1759567666145095807) 2024-02-19T13:16Z [----] followers, [----] engagements "@fluffer9 Im not allowed to sell some of my $VKTX shares Im not allowed to invest in anything else Dont forget I got into $LUNR too. This is ridiculous. Im not allowed to tweet about anything else other than $VKTX" [X Link](https://x.com/BIOTECHSCANNER/status/1759568571909243200) 2024-02-19T13:20Z [----] followers, [---] engagements "$IOVA $LUNR $VKTX Tuesday 🚀" [X Link](https://x.com/BIOTECHSCANNER/status/1759572444430446751) 2024-02-19T13:35Z [----] followers, [----] engagements "$LUNR - rooting for advancement of humanity in space. $IOVA - Rooting for fewer funerals because of cancer. Its more than just money. But gladly accept the opportunity that investing provides" [X Link](https://x.com/BIOTECHSCANNER/status/1759588462561235367) 2024-02-19T14:39Z [----] followers, [----] engagements "$IOVA- Think long term on this one. That is why its in my IRA account. This approval as I mentioned previously is just a stepping stone. The next big catalyst and I would argue is the biggest in the companys history is TILVANCE [---] confirmatory trial. Oh the buyout target on its back is getting bigger by the day. Patience" [X Link](https://x.com/BIOTECHSCANNER/status/1759951548593938876) 2024-02-20T14:42Z [----] followers, [----] engagements "$LUNR - we are heading to the moon in every sense of the word" [X Link](https://x.com/BIOTECHSCANNER/status/1759962556284784828) 2024-02-20T15:25Z [----] followers, [----] engagements "$IOVA- Investors on offering:" [X Link](https://x.com/BIOTECHSCANNER/status/1759988004620304525) 2024-02-20T17:06Z [----] followers, [----] engagements "The most profitable way to trade biotech is through catalysts and getting in early. After identifying a solid company that checks out using my qualifications the risks are much much lower and you dont even have to hold through the catalysts $VKTX is a great example We are still waiting on catalysts" [X Link](https://x.com/BIOTECHSCANNER/status/1760140950934814787) 2024-02-21T03:14Z [----] followers, [----] engagements "$AQST- Anaphylm will change the treatment paradigm for severe allergic reactions and anaphylaxis. Study after study show that people are not carrying the EpiPen and Audi-Q with them. The medication may be damaged. Not with Anaphylm. Its heat freez crash ( run over by a car and still undamaged. Say goodbye to the painful injections. Just put Anaphylm under the tongue without the need to swallow Game changer" [X Link](https://x.com/BIOTECHSCANNER/status/1760683210554712432) 2024-02-22T15:09Z [----] followers, [----] engagements "$AQST - watch this to meet the management team. CEO is very sharp" [X Link](https://x.com/BIOTECHSCANNER/status/1760684563997880621) 2024-02-22T15:14Z [----] followers, [----] engagements "$AQST - Anaphylm (Sublingual Epinephrine) doesnt just matched the efficacy and safety of EpiPen (Pfizer) and Audi-Q (Sanofi) it outperforms them. Drug concentration is similar or better but what makes Anaphylm shine is the Mean Arterial Pressure (MAP). EpiPen and Audi-Q do not maintain MAP and consequently patients will faint due to low blood pressure and decreasing blood flow to vital organs. On the other hand Anaphylm seems to do that very well" [X Link](https://x.com/BIOTECHSCANNER/status/1760691069371736140) 2024-02-22T15:40Z [----] followers, [----] engagements "@georgedemirakos I have trimmed both of my positions to make room for $AQST. But I still have a nice chunk in my portfolio for $VKTX $IOVA $ARQT and $FUSN. I am out of $LUNR" [X Link](https://x.com/BIOTECHSCANNER/status/1760695120532328880) 2024-02-22T15:56Z [----] followers, [----] engagements "$AQST - Today ARS Pharma $SPRY announced positive top line data that addresses the CRL (Complete Response Letter) from the FDA. More like a rejection letter but in this situation it was not that severe. As I mentioned before not all CRL are catastrophic Sometimes the FDA just says hey do this too in a trial so we can make sure your drug is safe. Unfortunately most uninformed investors panic and lose their shares and money. $SPRY shares tanked on that news several months back. Glad they got positive results. This situation TOTALLY benefited $AQST because they went ahead and added the REPEATED" [X Link](https://x.com/BIOTECHSCANNER/status/1760738659706318865) 2024-02-22T18:49Z [----] followers, [----] engagements "$LUNR - my second favorite hobby - astrophysics. Loving every minute of the launch and landing. Go" [X Link](https://x.com/BIOTECHSCANNER/status/1760868627094425625) 2024-02-23T03:26Z [----] followers, [----] engagements "$LUNR - Odysseus is on its side but it seems like they still will be able to execute most of the goals of the scientific payloads. Biggest issue they mentioned is the antennas are pointing forward towards the moon so that communication with Odysseus may be a challenge. They said this event taught them a lot for future missions especially with the navigation lidar system. They will have compliment systems so that when [--] failed the other will compensate. The biggest problem with this mission was the lazer on the lidar that supposed to give depth perception didnt work. They will get it right." [X Link](https://x.com/BIOTECHSCANNER/status/1761396078077686223) 2024-02-24T14:22Z [----] followers, [---] engagements "$AQST - Since it is really time consuming when doing thorough research on a company that I am interested in one of the first things that I look at is the market cap and what I can potentially gained in short medium and long term if I choose to go long. Then I look at the products the company is making. At this point Im asking myself what is the total addressable market (TAM) for the products. Usually there are multiple products or drugs but there is usually the main one that I will focus on. My minimum potential gain for each company that I decide to invest in is at least 3X from my entry" [X Link](https://x.com/BIOTECHSCANNER/status/1761473752057938420) 2024-02-24T19:30Z [----] followers, [---] engagements "No. $2.5 billion is more realistic. I believe a $2.5- $3 billion buyout is very possible and likely. Pfizer is having nightmares. Kaleo too. Plus all of the generic auto injectors manufacturers. Poof. Gone. The moment $AQST Anaphylm appears on the market it will dominate because of UNMATCHED CONVENIENCE" [X Link](https://x.com/BIOTECHSCANNER/status/1761607297480942008) 2024-02-25T04:21Z [----] followers, [---] engagements "$AQST - As promised I am going to share with you a huge nugget that none has even given it a second thought when they saw it. In my qualifications #5 (Incremental success through various stages of clinical trials) is critical when deciding whether to invest in a certain biotech company. Why There is usually [--] very big drug that they are working on and the future pretty much depends on it. $IOVA - Its the trials for Amtagvy. Got approval because all the smaller trials prior to the pivotal phase [--] trial showed positive results. $VKTX will be the same with VK2809 VENTURE. Please get to the" [X Link](https://x.com/BIOTECHSCANNER/status/1761966631905841301) 2024-02-26T04:09Z [----] followers, [----] engagements "$ALT - Not in it but I did place a challenge to a debate that their short report was bogus. Written by a high school student with wrong conclusions. Love seeing them getting destroyed" [X Link](https://x.com/BIOTECHSCANNER/status/1762108854584721532) 2024-02-26T13:34Z [----] followers, [----] engagements "$AQST - Remember they dont just have drugs. They have a platform The CEO already talked about all of the possibilities of in and out licensing products for other companies. The possibility is massive. Read the company profile. Its all in there. They are very experienced in drug manufacturing" [X Link](https://x.com/BIOTECHSCANNER/status/1762163898076066122) 2024-02-26T17:13Z [----] followers, [---] engagements "$AQST - In medicine one of the biggest problems is DEVICE FAILURE. Most of the failures is due to incorrect usage or administration. Let me list the devices to treat severe allergic reactions and anaphylaxis: [--]. Manual Injection [--]. EpiPen (Mylan Pharmaceuticals owned by $PFE [--]. Auvi-Q (Kaleo Pharma). [--]. Neffy by $SPRY Let me list non-device treatments for severe allergic reactions and anaphylaxis [--]. Anaphylm by $AQST is the first and only non-device sublingual film to treat severe allergic reactions and anaphylaxis. So easy you know the rest" [X Link](https://x.com/BIOTECHSCANNER/status/1762259616337940492) 2024-02-26T23:33Z [----] followers, [----] engagements "$AQST - Anaphylm entering the market. You know what happens to its competitors💀" [X Link](https://x.com/BIOTECHSCANNER/status/1762287248790229025) 2024-02-27T01:23Z [----] followers, [----] engagements "$VKTX - I should definitely think about opening a psychic hotline. They got 14% and placebo adj 13%. Shorts will be destroyed. I also predicted a buyout. Thats next. $VKTX - Subq phase [--] VK2735 VENTURE trial if they get 15-17% weight reductions in just [--] weeks including titration the shorts will absolutely be destroyed. I think this is very achievable or exceeded btw. $VKTX - Subq phase [--] VK2735 VENTURE trial if they get 15-17% weight reductions in just [--] weeks including titration the shorts will absolutely be destroyed. I think this is very achievable or exceeded btw" [X Link](https://x.com/BIOTECHSCANNER/status/1762453528356757797) 2024-02-27T12:24Z [----] followers, [----] engagements "@jfmcrr They dont have anything on the market. In VK2735 a dual receptor agonist of GLP-1/GIP is the same combination as $LLY Mounjaro and Zepbound (Tirzepatide) and those drugs are amazing. $VKTX" [X Link](https://x.com/BIOTECHSCANNER/status/1762510209325346991) 2024-02-27T16:09Z [----] followers, [---] engagements "@HFK23x It depends on your risk tolerance. But never go all in for [--] ticker brother" [X Link](https://x.com/BIOTECHSCANNER/status/1762522494026564086) 2024-02-27T16:58Z [----] followers, [---] engagements "Much much higher. Look at 9/2018. It got to $20.70 with nothing basically. Thats several months after IPO. Now with $50 mil revenue [--] drugs on the market though very small size and [--] big ones coming. The biggest being Anaphylm. First ever non-device convenient treatment for severe allergic reactions and anaphylaxis. Then Libervant for seizures using the same film delivery system. Game changer for both" [X Link](https://x.com/BIOTECHSCANNER/status/1762543170917675509) 2024-02-27T18:20Z [----] followers, [---] engagements "$AQST - Pfizer Kaleo and ARS just got the news that Anaphylm will be coming to market. Their reaction:" [X Link](https://x.com/BIOTECHSCANNER/status/1762569222662574174) 2024-02-27T20:03Z [----] followers, [----] engagements "$VKTX - Offering" [X Link](https://x.com/BIOTECHSCANNER/status/1762589060999024966) 2024-02-27T21:22Z [----] followers, [----] engagements "$VKTX - If no buyout then I am going to apply for a VP of sales and marketing position. No chance. Buyout is 100% going to happen" [X Link](https://x.com/BIOTECHSCANNER/status/1762593911065694402) 2024-02-27T21:41Z [----] followers, [----] engagements "$AQST - You will see the cash burn rate is not that much. This company is very well run and pretty lean. The biggest cost for a startup biotech is clinical trials. Each trials can cost $100 mil or more. Not with $AQST. These trials are very different from typical trials where you enroll sick patients; getting them stablized on standard of care drugs then a wash out period etc again very time consuming and expensive. Take the trials for $VKTX for example. The offering today was for you guessed it- more trials. For $AQST remember they cant make people get to anaphylaxis. Thats unethical and not" [X Link](https://x.com/BIOTECHSCANNER/status/1762708974091088160) 2024-02-28T05:19Z [----] followers, [----] engagements "$AQST - I keep getting questions about their financials. Yes they have only $24 mil. But they are generating revenue unlike MANY of their biotech counterparts. Is there a chance of an offering Yes but their operations are not cash intensive like many others due to the low cost clinical trials. Even if they do an offering it probably to launch their products wouldnt you mind that After all you invested in a biotech to see them bringing products to the market to generate wealth and help patients right How did investors react to $VKTX offering yesterday $350 million VKTXs previous offering was" [X Link](https://x.com/BIOTECHSCANNER/status/1762817170994528534) 2024-02-28T12:28Z [----] followers, [----] engagements "Today we are going to talk about CONTEXT. You are following me so I am assuming that you are interested in investing in biotechs. To summarize what I do here is I find biotech companies and do thorough due diligence on them. I look at everything but especially their pipeline and determine if a company is worth my time and money. I dont like to lose so the companies have to pass a rigorous evaluation process before I pick them. I pinned the qualifications that I check off for each ticker. I encourage you to do the same. Now back to CONTEXT. You have to look at things in a bigger picture to put" [X Link](https://x.com/BIOTECHSCANNER/status/1762845245585187024) 2024-02-28T14:20Z [----] followers, [----] engagements "It will be a while before I release the next company that found that also has a PLATFORM. You will absolutely love this one. DD has been 75% done. What sector The white hot OBESITY. Has to be unique and game changing to be chosen. This one got it. Stay tuned dragons 🐉 (thats our mascot). Just came up with that. Hope you all approve Thoughts" [X Link](https://x.com/BIOTECHSCANNER/status/1762850787938504937) 2024-02-28T14:42Z [----] followers, [----] engagements "$IOVA $AQST I talked about context earlier. In the case of $AQST its financials. In $IOVA- If you look at their ORR (Objective Response Rate) of 39%. its pretty low in their pivotal trial that got them FDA approval for Amtagvi. HOWEVER These are the patients who are very sick and already talking to funeral planners. These patients have months some weeks or days. So you cant expect an ORR of 50% like with other forms of cancer. Context is so important. A huge part of data analysis" [X Link](https://x.com/BIOTECHSCANNER/status/1762867780393537551) 2024-02-28T15:50Z [----] followers, [----] engagements "$AQST Just so you understand. The potential I see in this company is the same as $VKTX if you look at market cap. I called $VKTX at $12. I saw 10X potential. Same with $AQST. I am an investor. If you are a flipper you may get frustrated with my tickers. If you dont notice by now I love gaming changing technology in a company. $AQST has EXACTLY that" [X Link](https://x.com/BIOTECHSCANNER/status/1762869871451205965) 2024-02-28T15:58Z [----] followers, [----] engagements "@sgonza33 More unknowns vs $VKTX thats all. I like $ALT but not enough to invest" [X Link](https://x.com/BIOTECHSCANNER/status/1762870502429724800) 2024-02-28T16:00Z [----] followers, [---] engagements "$AQST - Catalysts and timelines: [--]. 3/5/2024 - Earnings via PR- AH [--]. 3/6/2024 - Earnings call [--] am EST. [--]. By end of March Ph3 data release [--]. 4/28/2024 - PDUFA Libervant age 2-5. [--]. TBD - Announcement of partnership to launch pediatric Libervant [--]. TBD Start pediatric trial for Anaphylm [--]. Apply for NDA for Anaphylm by end of [----] [--]. PDUFA for Anaphylm - 2H [----] [--]. Launch Anaphylm - 2H [----] [--]. 1/11/2027 - Launch Libervant for adults [--] and up. [--]. If you are still in $AQST and I hope you will be congrats" [X Link](https://x.com/BIOTECHSCANNER/status/1762947248088846453) 2024-02-28T21:05Z [----] followers, [----] engagements "@ben_siravo @Mark748779211 Thanks for the great questions. [--]. Not bad for $LLY at all. Market potential is not reached. Still plenty of room for these drugs to coexist. [--]. $PFE and $BMY Then $AZN top [--] possible buyers" [X Link](https://x.com/BIOTECHSCANNER/status/1762948448091779211) 2024-02-28T21:10Z [----] followers, [---] engagements "Those [--] were picked because Pfizer tried to get in the Obesity market but failed with their compound. They have money to get the drug from VKTX. BMY. They have shown interest in Obesity as well. AZN brought the first GLP-1 to market with Byetta $AQST - PharmFilm technology was developed in house. Yes they can out license. That information is also on their website. This company has so much going for it. Thanks for the questions" [X Link](https://x.com/BIOTECHSCANNER/status/1762957830909288472) 2024-02-28T21:47Z [----] followers, [---] engagements "$AQST - Headquarters is in New Jersey. Massive pharmaceutical industry hub. Johnson and Johnson Merck Bristol Myers Squibb Novo Nordisk to name a few. Pfizer is close by in New York. These big boys will start noticing $AQST soon" [X Link](https://x.com/BIOTECHSCANNER/status/1762977851496628513) 2024-02-28T23:07Z [----] followers, [----] engagements "$VKTX - Never thought I would say this but I thought dilution risk for $VKTX is low but damn man Should I tell them to take a good look at $AQST EVERYONE should look at $AQST regardless. Upside is similar to $VKTX when it was $12" [X Link](https://x.com/BIOTECHSCANNER/status/1763030805436088814) 2024-02-29T02:37Z [----] followers, [----] engagements "$AQST - On July [--] [----] Aquestive Therapeutics introduced itself to the market on IPO day. Their quest: Advancing medicines Solving therapeutics problems Improving lives Less than [--] months later the share price shot up to $20.70 with only a dream. Here it is more than [--] years later it has the opportunity to prove imto the world that Anaphylm can save lives for patients suffering from severe allergic reactions and anaphylaxis in a phase [--] readout coming anytime in March. The magnitude of this topline data cannot be overstated. Even the CEO Dan Barber said on the Oppenheimer Science conference" [X Link](https://x.com/BIOTECHSCANNER/status/1763276855312826743) 2024-02-29T18:55Z [----] followers, [----] engagements "$AQST - dips will come but not many as we get closer to catalysts. [--]. Earnings 3/5 then the call on 3/6. After that a BIG one phase [--] data readout sometime in March. Could be same day as earnings call" [X Link](https://x.com/BIOTECHSCANNER/status/1763298235408367618) 2024-02-29T20:20Z [----] followers, [----] engagements "$AQST - Soon you will see it all over the news about the newest treatment option for severe allergic reactions and anaphylaxis and you can talk back to the TV or your smart phone. Yes I know this company. And I proudly own a piece of that company" [X Link](https://x.com/BIOTECHSCANNER/status/1763303677358481858) 2024-02-29T20:42Z [----] followers, [----] engagements "@rkpm33tang @georgedemirakos @wangruntu1988 Yes I do. $AZN is focusing on oncology quite a bit. $IOVA is in a great place with or without a buyout" [X Link](https://x.com/BIOTECHSCANNER/status/1763315177036845390) 2024-02-29T21:27Z [----] followers, [---] engagements "@deacon451 Nope. They are way behind $AQST and they still will have to wait until [----]. The ODE affects everyone. $AQST already got tentative approval. Jan [--] [----] is launch date" [X Link](https://x.com/BIOTECHSCANNER/status/1763324813261840635) 2024-02-29T22:06Z [----] followers, [---] engagements "$AQST - This company has experience. I really like the CEO Daniel Barber. He understands the sales and marketing side of the business really well. Another peace of mind for me because thats what I do" [X Link](https://x.com/BIOTECHSCANNER/status/1763337585009758328) 2024-02-29T22:56Z [----] followers, [----] engagements "@lovejklmn Not even close. Hot cold run over by a car and still be ok. Fits in a smartphone case. Thinner than a credit card. $AQST" [X Link](https://x.com/BIOTECHSCANNER/status/1763685477817733603) 2024-03-01T21:59Z [----] followers, [---] engagements "@TheRealDanSfera Lots. Go back and check out my previous posts" [X Link](https://x.com/BIOTECHSCANNER/status/1763953453678653449) 2024-03-02T15:44Z [----] followers, [---] engagements "$AQST - $SPRY $836 mil market cap to be exact. $283mil for $AQST. Yes its a shocker. @BIOTECHSCANNER Market cap of $283 is a shocker considering that the next closest innovator within this indication (ARS pharma) has a market cap of $700+. Stocks slept on. My question being is their strategy to out-license this product or commercially launch it themselves @BIOTECHSCANNER Market cap of $283 is a shocker considering that the next closest innovator within this indication (ARS pharma) has a market cap of $700+. Stocks slept on. My question being is their strategy to out-license this product or" [X Link](https://x.com/BIOTECHSCANNER/status/1764089433668616343) 2024-03-03T00:44Z [----] followers, [----] engagements "Welcome my new friends from South Korea. I had a privilege of working with International students from Japan South Korea Mainland China Hong Kong and Vietnam when I was a Director of International Student Recruitment at a university before I entered the pharmaceutical industry. I made many friends and still keep in contact with several. My wife wants to visit Japan this summer. We go to Seoul Korea but only inside Incheon Airport. Someday I want to visit South Korea too Thank you for spreading the good news about $AQST and Anaphylm" [X Link](https://x.com/BIOTECHSCANNER/status/1764487482219892771) 2024-03-04T03:06Z [----] followers, [----] engagements "@AethernCapital Thank you for your kind words. My followers including you deserve the best. Our livelihood depends on it" [X Link](https://x.com/BIOTECHSCANNER/status/1764617953264234998) 2024-03-04T11:44Z [----] followers, [---] engagements "@dvdbeaver1 My buyout price for $AQST is least $1.5B. Remember they have a platform in PharmFilm and drug permeation enhancement technology. The possibilities are endless. They also have a strong drug manufacturing experience as well" [X Link](https://x.com/BIOTECHSCANNER/status/1764642059875422244) 2024-03-04T13:20Z [----] followers, [---] engagements "There are companies that make lap bands for weight loss that you can invest in. I HIGHLY RECOMMEND NOT TO Why do you think that is Have you heard about a class of drugs called GLP-1 Cmon friends. Be smart. Respect your money. Our families depend on it. Be wise" [X Link](https://x.com/BIOTECHSCANNER/status/1764652244224360881) 2024-03-04T14:00Z [----] followers, [----] engagements "$AQST - Look at the previous analysis I have done especially on $VKTX $ARQT $CALT $IONS and $IOVA on approvals and data release. I know biotech analysis. That I know. $AQST at this level is a gift" [X Link](https://x.com/BIOTECHSCANNER/status/1764728698232508780) 2024-03-04T19:04Z [----] followers, [----] engagements "This right here is a big reason why you dont have more people devoted their time for the good of the investment community. Yes I am reconsidering doing this. People are so ungrateful. @BIOTECHSCANNER Why are you pumping so much @BIOTECHSCANNER Why are you pumping so much" [X Link](https://x.com/BIOTECHSCANNER/status/1764861049289740729) 2024-03-05T03:50Z [----] followers, [----] engagements "@pharmdaz I am a Dallas Mavericks fan. Please stop 😂. We got our revenge though" [X Link](https://x.com/BIOTECHSCANNER/status/1765129271633211635) 2024-03-05T21:36Z [----] followers, [---] engagements "@SexyStockSlayer Thats interesting. Thats wrong though as far as I know" [X Link](https://x.com/BIOTECHSCANNER/status/1765130495191654680) 2024-03-05T21:41Z [----] followers, [---] engagements "$AQST - We remain excited to see our topline pivotal data and continue to anticipate reporting topline data from our Anaphylm pivotal study this month. Highly recommend shorts to google Goodwill near me soon" [X Link](https://x.com/BIOTECHSCANNER/status/1765257845790908845) 2024-03-06T06:07Z [----] followers, [----] engagements "$PFE is a perfect company to buy $AQST. They have the sales force in the US and International. They have experienced selling epinephrine. An absolute perfect fit" [X Link](https://x.com/BIOTECHSCANNER/status/1765378984588595667) 2024-03-06T14:08Z [----] followers, [----] engagements "@MartyChargin They are too cheap for $VKTX because they waited for VENTURE results to come out. Now its too expensive. The more you look the more you pay. Thats how it works in biotech buyouts. They definitely can afford $AQST. Thats a drop in the bucket for them. $1.5 billion" [X Link](https://x.com/BIOTECHSCANNER/status/1765380706698453404) 2024-03-06T14:15Z [----] followers, [---] engagements "$AQST - You all heard from the management personally. I am very excited about the future of the company. The difference between others my myself is I make it known. I dont need to pump. I dont tell people to buy or to sell. I provide education when theres an unmet need in this community. Unfortunately there are some crazy folks on this platform who are mostly likely shorts. The biggest comfort factors that shorts have in their favor are [--]. Lack of information within the investment community. [--]. They play with investors fears. And without proper information investors are helpless. I am not" [X Link](https://x.com/BIOTECHSCANNER/status/1765383571324203318) 2024-03-06T14:26Z [----] followers, [----] engagements "$AQST - After a great earnings call and a huge phase [--] topline data coming in [--] weeks. People are losing precious shares" [X Link](https://x.com/BIOTECHSCANNER/status/1765387006706663468) 2024-03-06T14:40Z [----] followers, [----] engagements "$AQST - New analyst rating of a BUY and $8 PT. Hmm Who lost shares this morning" [X Link](https://x.com/BIOTECHSCANNER/status/1765414160299344140) 2024-03-06T16:28Z [----] followers, [----] engagements "$AQST- Not satisfied yet. Not even close. My conviction for this is the same as $VKTX. Patience. Amazing things happening here at $AQST. By the way they did use the words transformative and transformation on the earnings call" [X Link](https://x.com/BIOTECHSCANNER/status/1765479067703251110) 2024-03-06T20:46Z [----] followers, [----] engagements "$VKTX $NVO The news today on amycretin weight loss. This data was sent to Novo Nordisk employees via email [--] years ago. No I didnt buy any $NVO shares after receiving the email. Shoulda 😂. Was trading at $30 levels" [X Link](https://x.com/BIOTECHSCANNER/status/1765752864603857259) 2024-03-07T14:54Z [----] followers, [----] engagements "Please stop bashing $VKTX and $NVO. $LLY is a great company and amazing products. So as $NVO. I have friends at $NVO and $LLY. When I was at Novo we have the utmost respect for $LLY and vice versa. The market is massive for diabetes and obesity. This is not a zero sum game. The market can use [--] or more drugs to address these problems that cost society trillions and more coming. Personally I am rooting for all of them to succeed. The drop in prices for $VKTX and $LLY is unwarranted especially for $LLY. The more options physicians have the better because some patients may not tolerate one drug" [X Link](https://x.com/BIOTECHSCANNER/status/1765767217923137704) 2024-03-07T15:51Z [----] followers, [---] engagements "@Anders_Research @TheRealDanSfera I have not compared efficacy between the two because they have not been tested against each other. I only pointed out Anaphylm is more convenient" [X Link](https://x.com/BIOTECHSCANNER/status/1765894391430815912) 2024-03-08T00:16Z [----] followers, [---] engagements "@farazsid47 We have to wait until the company officially releases their data. That is the fairest way to treat the company. Let the data do the talking. I have my gut feelings about the oral VK2735. I am going to hold it" [X Link](https://x.com/BIOTECHSCANNER/status/1765974987150688631) 2024-03-08T05:37Z [----] followers, [---] engagements "The environment in the stomach is very acidic. The company has to put some type of coating around the peptide in this case VK2735 to protect it from acid destroying the GLP-1 before getting absorbed. $NVO has a technology for that with an absorption enhancer sodium N- (8- 2- hydroxybenzoyl amino) caprylate (SNAC) which facilitates the absorption of semaglutide across the gastric epithelium in a concentration dependent manner" [X Link](https://x.com/BIOTECHSCANNER/status/1766088527136088118) 2024-03-08T13:08Z [----] followers, [---] engagements "$AQST - Thanks for the follow. Heres the recording of the latest earnings call on March [--]. The CEO said worldwide Anaphylm sales can see surpass $1 billion per year. Libervant for 2-5 year old between $100-$200 million. This number will be higher when Libervant for adults is launched in January of [----]. Finally AQST [----] the cream for dermatology can get multi hundred million per year. Now look at the current market cap. This company is very under valued. Thanks for listening to the Oppenheimer conference. Please listen to this webcast for the latest updates" [X Link](https://x.com/BIOTECHSCANNER/status/1766617852608450820) 2024-03-10T00:11Z [----] followers, [---] engagements "@meputzke20 They probably dont have it yet. I am more confident today than when I first invested it $AQST especially after the earnings call. I think the management is to make a big splash on data day" [X Link](https://x.com/BIOTECHSCANNER/status/1766671915081511020) 2024-03-10T03:46Z [----] followers, [---] engagements "@TomHamil3 @meputzke20 Data day is not set. CEO said in [--] weeks on the earnings call on 3/6. If it is exactly [--] weeks then its on 3/20. $AQST" [X Link](https://x.com/BIOTECHSCANNER/status/1766789830413840471) 2024-03-10T11:34Z [----] followers, [---] engagements "@down_dogdiv For which ticker For $AQST it will probably be in billions by [----]. Please listen to the latest earnings call on 3/6/2024" [X Link](https://x.com/BIOTECHSCANNER/status/1766868300615630967) 2024-03-10T16:46Z [----] followers, [---] engagements "$AQST - I will write up what to expect from Phase [--] next weekend as we anticipate possible data release on 3/20 which is [--] weeks from the earnings call. On the call CEO Dan Barber said talk to you in [--] weeks. I cant tell you all how excited I am for this" [X Link](https://x.com/BIOTECHSCANNER/status/1767062631251124234) 2024-03-11T05:38Z [----] followers, [----] engagements "$AQST - CEO Dan Barber who is a very conservative person who is very deliberate with his statements because he knows the FDA is watching everything he says on Anaphylm. On 3/6/2024 during the earnings call he confidently stated that he expects global sales of Anaphylm once approved will exceed $1 billion. Libervant for 2-5 year olds (could launch this summer) $100-$200 million. These are only [--] main asset (Anaphylm) and a fraction of the other asset (Libervant for adults). Also the cream isnt counted yet. I understand the pharmaceutical industry market well because this is what I do. I can" [X Link](https://x.com/BIOTECHSCANNER/status/1767195039128576416) 2024-03-11T14:25Z [----] followers, [----] engagements "@Fire_Truck5 Market cap for $AQST is ridiculously low" [X Link](https://x.com/BIOTECHSCANNER/status/1767213559472111678) 2024-03-11T15:38Z [----] followers, [---] engagements "$AQST - Heres another prediction I made before the PDUFA date for $IONS. Again using my experience to analyze clinical trials and medication to the molecular level. This is part [--] of my prediction series" [X Link](https://x.com/BIOTECHSCANNER/status/1767544673755681182) 2024-03-12T13:34Z [----] followers, [----] engagements "@Liftthatbid @pharmdaz Much better upside with $AQST. SPRY [--] product. No rev. $AQST - [--] already generating $50.6 mil. Go to their websites. I have no doubt you will like $AQST more. The market cap is ridiculous low vs spry" [X Link](https://x.com/BIOTECHSCANNER/status/1767563043104325836) 2024-03-12T14:47Z [----] followers, [---] engagements "Yes. This is true. I saw this when I looked into SPRY. Still it doesnt change my risk assessment between the two. I still personally see a much better upside for $AQST. I look further ahead of what will be the preferred option and it will always be Anaphylm. Even if Neffy comes to market first. The moment Anaphylm arrives its over. Look at [--] diabetic drug call Invokana in the class of diabetes drugs called SGLT-2 inhibitors. It was first in class. First to market. Janssen doesnt even promote it anymore. Farxiga made it to the top [--] list that I shared yesterday. The market will sort it out" [X Link](https://x.com/BIOTECHSCANNER/status/1767662830948372614) 2024-03-12T21:23Z [----] followers, [---] engagements "$AQST- This is the Q4 earnings call on 3/6/2024. Please take a listen if you have not. Listening to this will get you caught up on the past present and future of the company. Its an exciting time to be investors in Aquestive Therapeutics for sure" [X Link](https://x.com/BIOTECHSCANNER/status/1767976861340999822) 2024-03-13T18:11Z [----] followers, [----] engagements "@gkrisrao @Anders_Research @Jonny_fun_guy They will do whatever is best for the company. They know much more than we do. I am very impressed with them. I wouldnt do an offering at this price. No way. I can tell they really like to keep the share structure lean for an especially if they want a buyout" [X Link](https://x.com/BIOTECHSCANNER/status/1768769467893293458) 2024-03-15T22:41Z [----] followers, [---] engagements "@OmerLandau1 @J313Ya CEO was talking about the 2-5 year olds sales potential. Remember he was saying globally. Notice he was saying launch as early as this year" [X Link](https://x.com/BIOTECHSCANNER/status/1769115762654846983) 2024-03-16T21:37Z [----] followers, [---] engagements "$FUSN - Family on 12/27/2023 I said $FUSN would be bought out by $AZN. Congrats to all Today: $FUSN - hitting [--] wk highs but dont let that scare you. This is a MAJOR buyout target. They have some of the best cancer assets on the market. I believe they will get bought out by $AZN at some point in $3-5 billion range. https://t.co/mzEI1LNAQ5 $FUSN - hitting [--] wk highs but dont let that scare you. This is a MAJOR buyout target. They have some of the best cancer assets on the market. I believe they will get bought out by $AZN at some point in $3-5 billion range. https://t.co/mzEI1LNAQ5" [X Link](https://x.com/BIOTECHSCANNER/status/1770046745424040341) 2024-03-19T11:16Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@BIOTECHSCANNER BIOTECH SCANNER
BIOTECH SCANNER posts on X about $iova, $aqst, $vktx, aur the most. They currently have [-----] followers and [----] posts still getting attention that total [------] engagements in the last [--] hours.
Engagements: [------] #
- [--] Week [---------] +8,323%
- [--] Month [---------] +1,752%
- [--] Months [---------] +491%
- [--] Year [---------] +31%
Mentions: [--] #
- [--] Week [--] -3.50%
- [--] Month [---] +5.80%
- [--] Months [---] +122%
- [--] Year [-----] -1.30%
Followers: [-----] #
- [--] Week [-----] +0.18%
- [--] Month [-----] +1.40%
- [--] Months [-----] +8.70%
- [--] Year [-----] +12%
CreatorRank: [---------] #
Social Influence
Social category influence finance cryptocurrencies stocks countries technology brands automotive brands currencies social networks vc firms exchanges
Social topic influence $iova #5, $aqst #3, $vktx, aur, investment, $rklb, $dawn, dawn, $gsrt, money
Top accounts mentioned or mentioned by @therealdansfera @america4life72 @marketmacher @henry431171040 @mucosalmelanoma @iovancebio @dansfera @firetruck5 @cricket99238 @thebrmola @hkdtweets @akmicic2 @pharmdaz @dancingtapas @mrdizle @operationatm @fdetranay @rushing9000 @iamn0tafanboy @pickledabs
Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA) Viking Therapeutics, Inc (VKTX) Rocket Lab USA, Inc. Common Stock (RKLB) Day One Biopharmaceuticals, Inc. (DAWN) ARS Pharmaceuticals, Inc. (SPRY) Frontline Ltd. (FRO) Auroracoin (AUR) NVIDIA Corp. (NVDA) Arcutis Biotherapeutics, Inc. (ARQT) Eli Lilly and Company (LLY) Novo-Nordisk (NVO) AltLayer (ALT) Intuitive Machines, Inc. (LUNR) McKesson Corporation (MCK) AstraZeneca PLC (AZN) Tesla, Inc. (TSLA) Calliditas Therapeutics AB (CALT) Viking Holdings Ltd (VIK) Fusion Pharmaceuticals Inc. (FUSN) Oklo Inc. (OKLO) RH (RH) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Uber Technologies, Inc. (UBER) Viatris Inc (VTRS) Merck & Co., Inc. (MRK) Pfizer, Inc. (PFE)
Top Social Posts
Top posts by engagements in the last [--] hours
"$NSAV so many catalysts: NSAVDEX Exchange with IBC technology + zero gas fees negotiating with Chinese crypto mining companies to join NSAV in the USA [--] crypto trading desks LuxFi NFT partnership VirtuaBroker Governance Token. What else Well glad you asked OTCQX"
X Link 2021-10-18T02:14Z [----] followers, [--] engagements
"$NSAV+ $CUBV very exciting week ahead. Lots of accumulation in anticipation of massive news. Its coming"
X Link 2021-11-05T20:31Z [----] followers, [--] engagements
"$NSAV The 51% with BW deal is in the works. Silverbear Capital specialty is guess what MERGERS AND ACQUISITIONS. $NSAV added another project with BW to be launched on Christmas Day. First of its kind and the idiots sold. Then panic selling began. $NSAV got stronger yesterday"
X Link 2021-11-17T14:15Z [----] followers, [--] engagements
"$NSAV if you dont believe the company will do what it said it will do then sell. As for me $NSAV will get it done. Mergers and acquisitions take time to complete. You only lose money if you sell for a loss. Patience will win out here"
X Link 2021-11-19T16:35Z [----] followers, [--] engagements
"January will be a very pivotal month for $NSAV. BW (51% acquisition) Vagabond (50%) Technicorum (5%) Metaverse Network partnership. Nirvana Meta partnership. OTC trading desks. Potential centralized exchanges (2). Very exciting. http://NSAVDEX.ORG http://NSAVDEX.IO http://NSAVDEX.ORG http://NSAVDEX.IO"
X Link 2022-01-06T15:38Z [----] followers, [--] engagements
"$NSAV - If you are looking to invest in the crypto/Metaverse/NFT/Mining industry $NSAV has the entire ecosystem. Their Centralized Exchange is undergoing TestFlight and in the process of applying for a license in the Philippines. [--] DEXes and crypto trading desks. Lots coming"
X Link 2022-03-23T14:10Z [----] followers, [--] engagements
"$NSAV - Besides having its own decentralized exchanges Centralized Exchange (in Test Flight) Crypto Trading Desks now crypto mining to the USA (soon) to the masses #REVENUE. https://www.stocktitan.net/news/NSAV/nsav-announces-launch-of-hive-the-first-blockchain-home-mining-guncxa8k72j0.html https://www.stocktitan.net/news/NSAV/nsav-announces-launch-of-hive-the-first-blockchain-home-mining-guncxa8k72j0.html"
X Link 2022-03-24T14:01Z [----] followers, [--] engagements
"$NSAV - Paper hands sold: [--] DEX CEX (coming 4/8) OTC trading desks NFT Market place HIVE crypto mining Technicorum +Influencio 50% Vagabond Uncharted collaboration (PR coming)share buyback AWallet managed by Silverbear Capital in HK with expertise in all things crypto"
X Link 2022-03-31T22:27Z [----] followers, [--] engagements
"$NSAV continues to add acquisitions and partnerships because its a holdings company. However its core business revolves around exchanges (crypto trading desks [--] DEX exchanges CEX NFT market place). Its Coinbase +more in its infancy. Patience my friends. Our time will come"
X Link 2022-04-23T15:07Z [----] followers, [--] engagements
"$NSAV - Disruptive market (DEX CEX NFT Crypto mining Crypto wallet Crypto trading desks GameFi SocioFi Coins Tokens Cybersecurity) patience required. Since Ive been asked a lot: Buy stock in several companies that make products & services that you believe in. Only sell if you think their products & services are trending worse. Dont panic when the market does. This will serve you well in the long-term. Since Ive been asked a lot: Buy stock in several companies that make products & services that you believe in. Only sell if you think their products & services are trending worse. Dont panic"
X Link 2022-05-01T14:16Z [----] followers, [--] engagements
"$NSAV - First of several benefits from announced loyalty program. Shareholders will get the Zayda Technologies Tokens based on their share counts and length of time they are holding. Zayda Techologies is a cybersecurity company going public in [----]. https://zaydatech.website/ https://zaydatech.website/"
X Link 2022-05-06T17:39Z [----] followers, [--] engagements
"@ChairmanOtc The one who tweets about $SIMPQ first 😀"
X Link 2022-07-08T23:51Z [----] followers, [--] engagements
"$ASTA- The time will come when the realization of missing an opportunity to generate multigenerational wealth for many traders. The company has been dropping hints on every tweet and PRs. They are all there. Dont miss this rocket. It will come"
X Link 2023-08-18T02:16Z [----] followers, [---] engagements
"$ASTA - Heres another capital venture that Astra Veda Corporation is involving in. Imagine when a medical device that will help millions of people sleep better at night getting FDA approval"
X Link 2023-08-24T04:51Z [----] followers, [---] engagements
"$ASTA - You are witnessing an amazing transformation of a brutal greedy dilution scheme from previous CEO into a legitimate Nasdaq technology venture capitalist company. How many OTC companies are doing what $ASTA is attempting to do It takes guts and courage"
X Link 2023-09-28T21:20Z [----] followers, [---] engagements
"@1EyedWilly8 Take your whatever is left in the $NSAV scam and invest in a legitimate company that is going to Nasdaq. $ASTA is the one"
X Link 2023-10-10T15:30Z [----] followers, [---] engagements
"$ASTA - While 99% of other OTC companies hide from FINRA and SEC due to their deceptive share selling schemes to enrich the crooked CEOs Astra Veda Corporation brings their legal team to Wall Street to meet with regulators. Yep. $ASTA is very different. #NASDAQ"
X Link 2023-10-11T15:06Z [----] followers, [---] engagements
"For months Ive been looking for a biotech company worth sharing. This [--] has everything: [--]. Lots of cash. (No dilution) [--]. Great pipeline. [--]. Solid clinical trials [--]. Very likely buyout candidate. [--]. Massive market (tens of billions per year). Ill release this ticker Sunday"
X Link 2023-12-01T03:19Z [---] followers, [---] engagements
"As promised here is the biotech company: Viking Therapeutics ($VKTX). This company I believe will yield massive returns in short and long term. $376 mil cash. Low dilution risk for 4-5 years. Amazing pipeline. Solid clinical data so far. Strong buyout candidate. Heres my take"
X Link 2023-12-04T00:18Z [---] followers, [---] engagements
"$VKTX - on its way to all time highs soon. Wait until more positive data on NASH and weight loss come out. Analysts PT low of $25 high of $40 average of $34. This is before new positive data coming out"
X Link 2023-12-05T15:54Z [---] followers, [---] engagements
"$VKTX - You know about Ozempic the drug that treats Type2 diabetes + massive weight loss benefits. I took part in the launch of Ozempic. Semaglutide is the molecule name. Did you know Viking Therapeutics VK2735 has already outperformed Semaglutide in clinical trials"
X Link 2023-12-06T17:40Z [---] followers, [---] engagements
"Viking Therapeutics $VKTX- Has a pipeline that makes Pfizer AstraZeneca Jensen Novartis Eli Lilly Novo Nordisk drool. Will be traded in triple digits by 1H [----] IMO. Institutions have been loading up on this company as well. Huge buyout candidate"
X Link 2023-12-07T18:34Z [---] followers, [---] engagements
"$VKTX - Unstoppable. Still ways to go. If you understand the pipeline of Viking Therapeutics and the market potential you would understand why I think this is heading towards triple digits"
X Link 2023-12-09T00:45Z [---] followers, [---] engagements
"$VKTX - Always on top of the list as a buyout candidate. I dont think the board would approve a buyout unless the money is really high like $15 to $20 billion because they know how awesome the pipeline is"
X Link 2023-12-12T23:10Z [---] followers, [---] engagements
"@Chuck80339031 $VKTX - It will with VK [----] (GLP1+GIP agonists) for obesity and cardiovascular diseases. It already demonstrated significant LDL reduction as well as weight loss. For NASH VK2809 phase 2b has best in class data. $VKTX will own the entire market [--] Non-Alcoholic Steatohepatitis"
X Link 2023-12-13T01:11Z [---] followers, [---] engagements
"$VKTX - VK2735 in phase 1: Day [--] that is [--] days after last dose got up to 7.8% weight loss with 10mg dose. liver fat by 47% in Non alcoholic fatty liver disease liver fat by 59% cholesterol by 21% LDL 23% APO(B) 21%. Phase [--] (Venture) 15mg dose will be more potent"
X Link 2023-12-13T16:20Z [---] followers, [---] engagements
"$VKTX- has the oral formulation of VK2735 a dual GLP-1/GIP agonists currently in phase [--]. The only oral GLP-1 on the market is Rybelsus a mono agonist. Novo Nordisk made $1.7 billions in sales in [----]. VK2735 will be much better than Rybelsus because of its dual action"
X Link 2023-12-13T21:36Z [---] followers, [---] engagements
"$ARQT - Roflumilast Foam phase [--] clinical trial: After [--] weeks of treatment 51% of patients had complete clearance of sebboreic dermatitis. With this data its almost impossible not to grant approval for the drug. PUDFA scheduled for tomorrow 12/16/2023"
X Link 2023-12-15T14:55Z [---] followers, [---] engagements
"$VKTX - Should be updating on phase [--] enrollment for VK2735 the once daily (QD) oral formulation of a dual GLP1-1/GIP agonist like MOUNJARO of Eli Lilly any day now. Very exciting. Read out is 2H [----]. The once weekly (QW) injectable version already trounced Ozempic"
X Link 2023-12-15T18:21Z [---] followers, [---] engagements
"$VKTX- VK2735 the dual GLP-1/GIP agonists to treat Obesity metabolic endocrine cardio diseases trial data will be positive since the injectable version is already destroying Ozempic. Massive revenue potential. By far my favorite biotech this year and many years to come"
X Link 2023-12-18T16:41Z [----] followers, [---] engagements
"$IONS - CEO + others buying before PUDFA. Hmm $IONS $AZN also seeking indication for - ATTR-CM which is a systemic progressive fatal condition that leads to progressive heart failure and death within [--] years from diagnosis. Already preparing [--] launch. Approval most likely"
X Link 2023-12-21T19:19Z [---] followers, [---] engagements
"$VKTX - By far my favorite biotech for [----]. Amazing pipeline with Dual GLP-1/GIP for Obesity + diabetes + NASH. Huge buyout target. 10X potential easy IMO. Biotech boom ahead in [----] top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal"
X Link 2023-12-23T00:43Z [---] followers, [---] engagements
"Merry Christmas friends. Wishing all of you a prosperous New Year with your investments. Lets get it 🤑"
X Link 2023-12-25T23:51Z [----] followers, [---] engagements
"$FUSN - hitting [--] wk highs but dont let that scare you. This is a MAJOR buyout target. They have some of the best cancer assets on the market. I believe they will get bought out by $AZN at some point in $3-5 billion range"
X Link 2023-12-27T22:27Z [----] followers, [---] engagements
"$VKTX and $FUSN - [----] will be extremely bullish and exciting. Both are huge buyout targets"
X Link 2023-12-29T16:47Z [----] followers, [---] engagements
"$VKTX- This is [--] of the most exciting biotech companies in [----]. Q1 - Topline results for VK2735 the oral formulation of GLP-1/GIP agonists. If data is positive it will be a huge buyout target. Cant wait"
X Link 2024-01-02T15:55Z [----] followers, [---] engagements
"$VKTX - Things are getting very serious. Several new form [--] just dropped. Massive insider buys: CEO - [------] shares. CFO - [------] shares. COO - [------] shares. Plus [--] other insiders. This tells me they are about to release data for oral VK2735 a dual GLP-/GIP agonist like Mounjaro a multi billion dollar diabetes drug with massive weight loss benefits"
X Link 2024-01-05T04:03Z [----] followers, [----] engagements
"$VKTX - Yep its a great company and buyout rumors are swirling around. I am long either way"
X Link 2024-01-09T20:02Z [----] followers, [---] engagements
"$VKTX - The only oral GLP-1 drug is Rybelsus. Novo Nordisk is making billions with. Im very confident oral VK2735 will blow Rybelsus out of the water due to its dual mechanisms of action of GLP-1 and GIP which will make VK2723 1st to a massive market of obesity+diabetes. Very exciting"
X Link 2024-01-09T21:30Z [----] followers, [----] engagements
"$VKTX - If $CYTK is valued at $10 B for [--] drug for HCM that affects [------] patients in the US. How much is $VKTX worth with a pipeline of NASH obesity diabetes and rare diseases Big pharma better bring their fat wallets to talk to $VKTX"
X Link 2024-01-10T00:47Z [---] followers, [----] engagements
"I love @AstraZeneca Great people with live saving products. However you need a to give yourself another chance in the GLP-1 space. You can do better than a Chinese oral GLP-1. Take a look at @Viking_VKTX. You are an amazing match for each other. Lets go $VKTX $AZN"
X Link 2024-01-10T02:51Z [----] followers, [---] engagements
"$VKTX - Data for oral VK2735 is coming in Q1. My experience with this class of drugs tells me that results will be great. This is the oral version of Eli Lillys injectable Mounjaro. It will be first oral dual GLP-1/GIP agonist to a $100B obesity market"
X Link 2024-01-11T15:40Z [----] followers, [---] engagements
"How familiar am I with the GLP-1 class Sales and marketing of Victoza the first GLP-1 injectable to market. Launched Ozempic then Rybelsus. All are great GLP-1 drugs. However the newer dual agonists like Mounjaro $LLY +VK2735 of $VKTX are much more efficacious"
X Link 2024-01-11T16:22Z [----] followers, [---] engagements
"$NVO $LLY and soon $VKTX $AMGN and other pharmaceutical companies with weight loss drugs that will rival bariatric surgeries. These surgery centers will essentially be pushed out due to high costs and risks"
X Link 2024-01-11T23:24Z [----] followers, [---] engagements
"@pharmacisting Another thing about Byetta the pen is clunky drug is not great. This is why AstraZeneca gave up on it. Its a once a day injection. Now we have a once weekly and in the future may have once monthly injection. But the game changer will be $VKTX with the oral GLP-1/GIP of VK2735"
X Link 2024-01-12T00:44Z [---] followers, [---] engagements
"$VKTX - $PFE (Pfizer) needs $VKTX in the worst way possible. $VKTX can revive the slumping giant. $PFE would be a smart investment in acquiring $VKTX and go after two big potential segments of hot biotech areas Obesity and Nash PFE has the resources to expedite the trials and bring both drugs to the market and gain on market share in Obesity vs $LLY Obesity is a pandemic $PFE would be a smart investment in acquiring $VKTX and go after two big potential segments of hot biotech areas Obesity and Nash PFE has the resources to expedite the trials and bring both drugs to the market and gain on"
X Link 2024-01-17T20:40Z [----] followers, [----] engagements
"@omarselim VK2735 by itself is worth $7-10B. Buying the entire $VKTX company I believe would be around $18 -20B. VK2809 is a legit NASH contender. So you can figure out the PT yourself"
X Link 2024-01-17T21:08Z [----] followers, [---] engagements
"$VKTX- Viking Therapeutics has a VERY LARGE buyout target on its back. Rybelsus is the only oral GLP-1 and its a mono-agonist indicated for Type II diabetes. Novo Nordisk is making billions. $VKTX has a dual GLP-1/GIP agonist in both oral and injectable forms. While working with Novo Nordisk I got to work with Victoza Ozempic and Rybelsus. Wegovy was launched [--] months after I left the company. If there is [--] thing I know I know this class of drugs like the backs of my hands. I also know that the dual agonists like Eli Lillys Mounjaro works better than Ozempic. I am expecting the same thing"
X Link 2024-01-18T02:16Z [----] followers, 28.1K engagements
"$VKTX - VK2735 oral formulation will be first in class and a game changer if data is good. I believe it will be great. When given a choice most patients prefer pills over injections. I believe VK2735 oral will expand the market potential massively as mentioned in PR. This is a $100 billion industry. Novo Nordisk and Eli Lilly are dealing with shortages. I spoke to a former coworker at Novo Nordisk last week and he confirmed the shortages. The market could use more drugs in this class. A lot more"
X Link 2024-01-18T19:23Z [----] followers, [----] engagements
"It really depends if the buyout is just for the drug or the entire company. If the buyout is for the company if I were $VKTX I would negotiate for a higher price due to their assets in NASH with VK2809 that is doing very well in clinical trials. They also have a drug for Rare disease as well. Then you bring in VK2735 in both formulation. I would not take anything less than [--] to [--] billion for the entire company. VK2809 may be first to market and will generate billions per year for years to come. Their assets are pretty impressive. Just my opinion"
X Link 2024-01-18T20:14Z [----] followers, [---] engagements
"@semodough @Pharmdca Im glad to hear because people think Im crazy saying $VKTX has a massive target on its back for acquisition"
X Link 2024-01-18T22:46Z [----] followers, [---] engagements
"Great question and I appreciate it. Its a great company with amazing pipeline. With that comes great demands for their drugs. More than likely they dont have the manufacturing capability and a sales and marketing team yet. That will take quite a bit of time and money. However they are still early as far as the product lifecycle: VK2735 Phase 1-2 for GLP-1/GIP. VK2809 phase 2b. Therefore they still have time to get all that done. This is why I believe $VKTX wouldnt mind being acquired by $PFE or $AZN for example because all of those disadvantages will be solved instantly. I hope that answered"
X Link 2024-01-19T00:38Z [----] followers, [---] engagements
"@omarselim They have not announced. I am not surprised if they are waiting on initial data on oral VK2735. If thats positive my buyout price of $15-20 billion for the entire company is very reasonable"
X Link 2024-01-19T16:51Z [----] followers, [---] engagements
"@Carflos223Matos @omarselim Not yet but never say never. My PT for $VKTX is with or without buyout. I absolutely love the pipeline of this company. I believe the price will be high double digits by eoy. Triple digits in 3-5 years"
X Link 2024-01-19T17:06Z [----] followers, [---] engagements
"$VKTX - For the record I invested in the company because of its amazing pipeline and long term growth not because of a buyout. If a buyout happens great If not still great"
X Link 2024-01-19T19:39Z [----] followers, [---] engagements
"$VKTX I got to work with Pfizer $PFE counterparts on a respiratory product while working at Boehringer-Ingelheim Pharmaceuticals several years back. They have great manufacturing facilities and a massive sales force. If Pfizer would buy $VKTX the entire company would be revitalized and immediately becoming a contender in the diabetes obesity and NASH space. This union makes perfect sense"
X Link 2024-01-19T22:53Z [----] followers, [----] engagements
"$GPCR their GLP-1 mono agonist GSBR [----] looks ok. I believe $VKTX Dual agonist GLP-1+GIP oral VK2735 will be more potent. As a general rule the more receptors involved the better. In this case a patient taking VK2735 will be basically taking [--] gut hormones (incretins) instead of just one with GSBR [----]. In the very near future you will start seeing combinations of GLP-1+ Glucagon GLP-1 + Amylase (inside info there) GPP-1 + GIP+ Glucagon and a couple more. Mono agonist that only works with GLP-1 will not be the drug of choice. Hope that helps"
X Link 2024-01-19T23:21Z [----] followers, [----] engagements
"$VKTX - Why do I invested in Viking Therapeutics and not others within the GLP-1 space with other dual agonists like GLP-1+Glucagon and other combinations Simple. Because $VKTX - has a dual agonist - VK2735 (GLP-1+GIP) that is similar to Eli Lillys Zepbound (obesity) and Mounjaro (Type [--] diabetes). The risk is MUCH lower because the combination is already proven to be extremely effective in both obesity and Type [--] diabetes on the market. Currently that is the only GLP-1 combination available on the market. Another reason Based on phase [--] data safety+efficacy profile was excellent. $VKTX said"
X Link 2024-01-22T07:05Z [----] followers, [----] engagements
"$VKTX- VK2735 patients still achieved statistically significant weight loss on day 43; that is [--] days after their last dose. The weight loss benefit was long lasting. An important marker of sustained efficacy. Yes they have a golden egg on their hands"
X Link 2024-01-22T16:25Z [----] followers, [----] engagements
"$VKTX - Jim Cramer suggested that if $TSLA shares would continue to drop that $LLY Eli Lilly with a market cap of approximately $600 would replace Tesla as [--] of the Magnificent [--]. Tirzepatide a GLP-1/GIP dual agonist under the brand name Zepbound for obesity and Mounjaro for Type [--] is responsible for a huge part of $LLY growth. Potentially leading it to be the first pharmaceutical company to reach $1 trillion dollar market cap. In case you havent heard $VKTX has a drug called VK2735 with the same combination and mechanism of action as Zepbound and Mounjaro that has performed very well in"
X Link 2024-01-23T06:13Z [----] followers, [----] engagements
"$VKTX - People sometimes ask me if the stock will tank if the results for the oral formulation of VK2735 is not good. My answer is ask yourself: Does Eli Lilly $LLY a $600 billion pharmaceutical company making billions and billions with [--] drug -Tirzepatide in the names of Zepbound for obesity and Mounjaro for Type [--] diabetes have an oral formulation of Tirzepatide No So if injectable (subq) VK2735 is showing extremely good data so far and could even be better than Tirzepatide does it matter if the oral version of VK2735 didnt do well in clinical trials No Because $VKTX will still make"
X Link 2024-01-24T08:36Z [----] followers, 11.8K engagements
"@stevebaldwin25 @semodough I have a long term goal with $VKTX. I am an investor more than a trader. I do trade certain stocks but $VKTX is part of my long term portfolio. Not going to give pt but the sp is going much much higher than where it is today"
X Link 2024-01-24T14:54Z [----] followers, [---] engagements
"$VKTX - I always get a funny feeling on big dips because Im thinking do they know what they are selling If you want to gauge the potential for $VKTX look at $LLY and $NVO and realize that the company has a drug in clinical trials right now that is as good or better than these companies drugs. IYKYK. Thats all I can say"
X Link 2024-01-24T18:02Z [----] followers, [---] engagements
"$VKTX - I would love to be on the sales and marketing leadership team once VK2735 is approved @Viking_VKTX. Lets kick some $LLY and $NVO a$$"
X Link 2024-01-24T20:27Z [----] followers, [---] engagements
"$VKTX - tomorrow will be exactly [--] months since @Viking_VKTX reports its earnings. Its definitely not going to be tomorrow. The buyout rumors are getting louder. Could it be Or waiting on oral VK2735 data Hmm"
X Link 2024-01-25T02:01Z [----] followers, [---] engagements
"$VKTX - Another buyout rumor"
X Link 2024-01-25T02:20Z [----] followers, [----] engagements
"It depends on your goal and your entry. I am sure its pretty low on the entry. Congrats. When you first get into $VKTX what price did you have in mind. Im in the pharmaceutical industry and I get to see sales and revenues from these drugs: Victoza Rybelsus and Ozempic when I was with Novo Nordisk. What I have seen from VK2735 is $VKTX has a very good and efficacious drug that has a potential to rival Mounjaro and Zepbound. I know for certain it will destroy Ozempic and Wegovy. My goal for VKTX is pretty high. I have quite a bit more than you but at a much higher entry. Thanks for the"
X Link 2024-01-25T14:01Z [----] followers, [---] engagements
"$VKTX - VK2735 was internally developed and chosen as stated We are developing a unique series of novel dual agonists of the glucagon-like peptide [--] (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders such as obesity NASH and certain rare disorders. Our lead clinical programs drug candidate is VK2735. Data announced during the first quarter of [----] from a Phase [--] trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive"
X Link 2024-01-25T23:05Z [----] followers, [----] engagements
"$VKTX - VK2735 part [--] - Subcutaneous formulation is GLP-1 + GIP dual agonist just like Mounjaro or Zepbound from Eli Lilly. The company hasnt released the molecular structure for VK2735 yet but it will be very similar yet slightly different. GLP-1 and GIP are gut hormones that are released by the L-cell in the case of GLP-1 and K-cells for GIP after a meal. After eating a meal the blood sugar level will increase from the carbohydrates that we ate. The hormone GLP-1 will cause the beta cells in the pancreas to release insulin to make sure blood sugar level remains normal. I could go into more"
X Link 2024-01-25T23:53Z [----] followers, [----] engagements
"$VKTX -VK2735 part [--] - Oral VK2735 - This will be the first GLP-1 /GIP oral agent to market if Viking Therapeutics can get it there. This will complement the subcutaneous version really well as pointed out by the CEO Brian Lian via communications. There is only [--] oral but its a mono GLP-1 agonist Rybelsus (I also launched). Its effectiveness is not anywhere near as good as its subcutaneous version Ozempic. I expect this will be the same with VK2735 oral vs the subq version. Why Because there is a substance in the stomach called acid. And its brutal for peptides. This is why there is no oral"
X Link 2024-01-26T00:35Z [----] followers, [----] engagements
"@KVGR87 $AMGN - make sense due to his relationships with them. However Amgen has a really good obesity drug in its pipeline as well. I think he would prefer $AMGN because thats where he came from. Thanks for the suggestion"
X Link 2024-01-27T04:10Z [----] followers, [---] engagements
"$VKTX - Really cool watching this: On July [--] [----] members of the Viking Therapeutics team visited the Nasdaq MarketSite in New Yorks Times Square to ring the opening bell. There will be very happy faces like the ones you see here after the buyout. They deserve the rewards for the tireless work that they have done"
X Link 2024-01-27T19:23Z [----] followers, [---] engagements
"$VKTX - Roche bought Carmot Therapeutics Inc for $2.7b with basically [--] molecule- a GLP-1/GIP dual agonist. They also have an oral mono agonist GLP-1. The oral GLP-1 will be meh at best. Thats really about all. $VKTX - pipeline is so much more attractive and game changing potential. VK2809 for NASH looking great and waiting for [--] week biopsy confirmation. This by itself is worth more than $2.7b. Then the King Kong of obesity and diabetes and other endocrine disorders in VK2735 subcutaneous once weekly formulation. This is another at least $3b. But here is where the fun begins- Oral VK2735"
X Link 2024-01-28T00:17Z [----] followers, [----] engagements
"$VKTX- My top [--] big pharma companies that WILL acquire Viking Therapeutics: [--]. $PFE market cap $155B they can afford $10-15B easily. Recently failed on their twice a day (BID) oral GLP-1 for obesity. I think they still have not given up on the GLP-1 gold rush. [--]. $BMY market cap $101B can also afford to buy $VKTX. Bristol Myers Squibb also recently gave up on BMS-986036 for NASH. VK2809 looks pretty attractive right now. Also VK3735 shows tremendous liver fat reduction and a potential combination of VK2809 and VK2735 as briefly discussed during the Q3 [----] earnings call. Lastly $VKTX Senior"
X Link 2024-01-28T05:31Z [----] followers, [----] engagements
"$VKTX- I really like the way CEO Brian Lian describes his thoughts about complementary use case for oral and subq VK2735. He basically says dont expect oral VK2735 to attain the same efficacy as subq. This is true and always be true unless we found a way to increase bioavailability of peptides in the stomach significantly. Right now its around .4-1% with Rybelsus. Novo Nordisk co-formulated Semaglutide with Salcaprozate sodium to improve absorption. The drugs have to overcome a highly acidic environment and a mucous lining that coats the intestines so scientists have to reduce the acidity in"
X Link 2024-01-28T19:15Z [----] followers, [----] engagements
"Yes he did. This is because they are more focused than the PK (pharmacokinetic- what the body does to the drug- absorption and elimination) and some PD (pharmacodynamics - what the drug does to the body such as glucose reduction and weight loss. Phase [--] is where the focus is more on PD. He sets the expectations low and he should"
X Link 2024-01-29T02:54Z [----] followers, [--] engagements
"@Bios4L True. But remember CEO COO CFO CSO (Chief Scientist) and other high ranking officials want it too"
X Link 2024-01-29T16:21Z [----] followers, [---] engagements
"$VKTX- To invest in biotechs you have to try to think like a CEO of every company either large or small. This will help you reduce your risks as you make investments decisions. Why do I keep saying $VKTX is an infinitely better buyout target with VK2735 (GLP-1/GIP) dual receptor agonist than other companies with other GLP-1 mono or dual agonists Simple: RISKS. Known vs unknown. Exhibit A: Roche to acquire Carmot at a purchase price of $2.7 billion upfront and the potential for $400 million in milestone payments. Roche chose Carmot because of the dual receptor agonist CT-388 (GLP-1/GIP). This"
X Link 2024-01-30T04:52Z [----] followers, [----] engagements
"$VKTX - Look how much $NVO is making from Ozempic and Wegovy. These are mono GLP-1 receptor agonist. VK2735 will perform better than these. $NVO [----] revenues: -Ozempic $13.9B USD. 66% coming from US. -Wegovy $4.5B USD. 94% coming from US. These two products generated 55% of Novo's [----] revenue up from 37% in [----]. Annual report: https://t.co/WzRujiOiXt $NVO [----] revenues: -Ozempic $13.9B USD. 66% coming from US. -Wegovy $4.5B USD. 94% coming from US. These two products generated 55% of Novo's [----] revenue up from 37% in [----]. Annual report: https://t.co/WzRujiOiXt"
X Link 2024-01-31T13:34Z [----] followers, 18.4K engagements
"$VKTX - Lets talk about advantages and disadvantages between oral VK2735 and Subq form. Subq: Advantages: [--]. Unrivaled efficacy. A patient gets an instant boost of the analog incretin hormones (GLP-1 GIP) in the body. [--]. Once weekly dosing (QW) is very convenient. You can give your self an injection and go on a week vacation without having to carry the drug with you. [--]. The pain in minimal with injections. Disadvantages Subq: [--]. The needle fear is strong no matter how we spin it. [--]. Pain is minimal but it creates anxiety. [--] May require refrigeration in certain situations. [--]. If you have"
X Link 2024-01-31T20:35Z [----] followers, [----] engagements
"I would be shocked if there is ONLY [--] unidentified suitors I am kind of torn between wanting $VKTX to get bought out and for it to partner with big pharma so they could actually make money money on these drugs down the road. You saw what $NVO made on Ozempic-$13b. Thats [--] year with shortages This is why I said $15-20b price tag for the entire company. Remember $VKTX has a really good molecule VK2809 for NASH too Big pharma will make their money back in no time People think I being unreasonable but have they touched Ozempic Victoza Mounjaro Rybelsus Seeing sales numbers in meetings I have"
X Link 2024-01-31T22:57Z [----] followers, [----] engagements
"$VKTX - My expectations for oral VK2735 body weight reduction is pretty muted because I understand and accept the challenges the stomach presents to large molecules like GLP-1 or GIP. The large the molecule the harder it is to be absorbed. I can go deeper into the molecular level but not necessary. VK2735 is larger because it has is a dual receptor agonist. You may notice most companies go with a mono agonist GLP-1 instead of a dual agonist GLP-1/GIP. This is not by accident. $VKTX is going for a home run here. They already know how good the subq version is. So the risk of going for a dual"
X Link 2024-02-01T01:48Z [----] followers, [----] engagements
"$VKTX- buyout or not. VK2735 is badly needed in the market to ease the shortage. 7.8% weight loss adj. mean and 6% placebo adjusted in [--] weeks with a low and mid dose is ridiculously good. The weight loss was maintained [--] days after the last dose Now you know why the tremendous interest in the VENTURE trial: The trial was designed to enroll approximately [---] adults who are obese (BMI [--] kg/m2) or adults who are overweight (BMI [--] kg/m2) with at least one weight-related comorbid condition. Due to heightened clinician and patient interest the trial's enrollment target was increased to 176"
X Link 2024-02-01T15:26Z [----] followers, [----] engagements
"$VKTX - The most exciting part about VK2735 Phase [--] trial is the very very low side effects. Viking was smart because as I told you yesterday the side effects of this class of drugs can be really bad. Mostly nausea and vomiting. When Trulicity came out there were reports of projectile vomiting. Yep Sorry for ruining your lunch. So the 5mg and [--] mg got really good efficacy without bad side effects. This allows them to increase the high dose (10mg) by 50% to 15mg in the Phase [--] VENTURE trial. They believe VK2735 has plenty of room to achieve more efficacy without increasing too much side"
X Link 2024-02-01T16:03Z [----] followers, [----] engagements
"Thanks for sharing this. Several people have asked me about $ALT Pemvidutide a dual GLP-1/Glucagon receptor agonist versus VK2735 a dual GLP-1/GIP receptor agonist. It is not surprising that VK2735 outperforms Pemvidutide. As I stated before GLP-1/GIP is a known and proven asset on the market- Mounjaro and Zepbound (Tirzepatide) whereas GLP-1/Glucagon is still an unknown and unproven molecule. Pemvidutide looks decent and I believe will do well once approved but will always fall behind Tirzepatide and VK2735 (still waiting on VENTURE). I also mentioned previously that Roche just acquired"
X Link 2024-02-02T04:25Z [----] followers, [--] engagements
"$VKTX - Many are curious about the phase [--] VENTURE trial of VK2735 and how its going to perform. You have seen [--] solid examples of how subq dual GLP-1/GIP receptor agonist: [--] and its a big one Eli Lillys $LLY Tirzepatide (Zepbound and Mounjaro) these [--] drugs will fuel Lilly for the next [--] years or more. [--]. Carmot CT-388. [--]. VK2735 itself in its phase [--] trial with 6% weight loss placebo adjusted and adjusted mean of [---.%] in just [--] weeks is very very very good and has potential to be best in class including Tirzepatide. And they have not even used the highest dose of 15mg in the phase [--] trial"
X Link 2024-02-02T15:23Z [----] followers, [----] engagements
"$VKTX - Yes thats right. You will not be able to find a subq GLP-1/GIP dual receptor agonist performing badly in clinical trials. You should expect and anticipate great results from the phase [--] VENTURE trial with VK2735 that already giving you a glimpse of its potentially best in class results in a phase [--] trial. Its not like you have not seen anything at all. Dont let the shorts scare you. Science is on our side here"
X Link 2024-02-02T16:39Z [----] followers, [----] engagements
"VENTURE trial data for subq VK2735 is between now and end of June [----]. Oral VK2735 in between now and end of March. Earnings call is next Wednesday February [--] after market. I dont know if we are getting data on oral or subq or not. Its coming soon though. I am very excited about it"
X Link 2024-02-02T17:02Z [----] followers, [---] engagements
"$VKTX - Just a reminder Novo Nordisk $NVO Rybelsus gets about [--] lbs weight loss with 7mg and 5lbs with 14mg dose. And its making billions. Oral VK2735 I believe will easily surpass that"
X Link 2024-02-02T20:11Z [----] followers, [----] engagements
"You shouldnt worry. You should feel even more confident. The point is ALL GLP-1/GIP that have put through at least a phase [--] trial have passed with flying colors. I have not mentioned this before but you technically cannot compare trials because the participants baselines demographics are different from another. The only thing that is important is that results are somewhat close. Why Because the patients outside of clinical trials are wildly different from one another. But overall the results should be similar to what we see in clinical trials. For example if VK2735 gets 15% in the VENTURE"
X Link 2024-02-03T02:08Z [----] followers, [---] engagements
"$VKTX - Management can totally destroy shorts with potentially positive VENTURE data. Icing on the cake would be great tolerability and safety profile and 2-3% weight reduction with oral VK2735. Remember oral is still phase [--]. They can make all kinds of adjustments to it in phase [--]. I believe shorts will be trapped here. Science is on our side. Safety is on our side. Efficacy is on our side"
X Link 2024-02-05T15:54Z [----] followers, [----] engagements
"I like $VKTX molecule better just because its proven. VK2735 subq is almost identical to that of $LLY Mounjaro and Zepbound. These two drugs will eventually dominate the diabetes and obesity market. They basically are doing that already. VK2735 actually showed better results than those at [--] weeks not even with the highest dose. I believe $VKTX is about to make a huge splash in the over $100B market. If it showed best in class data in VENTURE here soon you me and the rest of us longs are going to be very happy. I think VENTURE will show best in class data or close to it"
X Link 2024-02-05T16:51Z [----] followers, [---] engagements
"$VKTX - WARNING ⛔ to shorts. Get out while you can. You are basically shorting a proven asset (GLP-1/GIP dual receptor agonist). Look no further than Mounjaro and Zepbound. VK2735 is almost the same drug that has shown to be even better at [--] weeks in phase [--]. Now in phase [--] with a longer duration and a higher dose. Again you are going to get destroyed. Be smart"
X Link 2024-02-05T19:41Z [----] followers, [----] engagements
"$VKTX- This is why I think shorts are trapped. Its a lose - lose situation if data is great which I am very confident that it will be. This person brought up this issue which plays right into what many shareholders management and staff at $VKTX are hoping for a buyout. If not then a partnership. Either way $VKTX will absolutely fly. The very fact that $VKTX doesnt have a manufacturing facility is the reason why its on everyones top merger and acquisition list Shorts are trapped. @BIOTECHSCANNER even if successful the operational challenge of manufacture at scale will render the product a"
X Link 2024-02-05T20:37Z [----] followers, [----] engagements
"$VKTX- I love a biotech startup with a great pipeline and no manufacturing plant. A perfect recipe for a buyout or partnership with big pharma. Shorts are in serious trouble. Deservedly so. Leerink $VKTX Management previously noted that external business development interest in their obesity program remains high along with several discussions centered on the companys NASH program- earnings 2/7 will be closely watched Leerink $VKTX Management previously noted that external business development interest in their obesity program remains high along with several discussions centered on the"
X Link 2024-02-05T23:06Z [----] followers, [----] engagements
"Thanks for your input. Totally agree with you. This is why I have been pounding the table on $VKTX is the fact that their drug VK2735 is kind of already on the market $LLY Mounjaro and Zepbound did all the trail blazing for the GLP-1/GPI dual agonists. Now all $VKTX has to do is to match or out match them in VENTURE. This is regardless of the oral. They will make tens of billions on the subq alone. However I think CEO wants the oral VK2735 to do well slso so he can get a bigger yacht after buyout. There is no way that $VKTX is not getting bought out"
X Link 2024-02-06T03:27Z [----] followers, [----] engagements
"$VKTX - I appreciate those of you sharing your knowledge because I believe education is highly lacking for biotech investors. We can help each other to be wiser investors and not flippers. So why do you think I keep bringing up Eli Lilly $LLY Mounjaro and Zepbound when I talk about $VKTX and its lead molecule for obesity VK2735 In the medical profession and the pharmaceutical industry there is a very widely known and accepted concept called CLASS EFFECT. Those who dont know you definitely should find out before you invest another penny in any biotech"
X Link 2024-02-06T12:32Z [----] followers, [----] engagements
"Friends please listen to me about this: Do not pay to join these Discord servers so they can pre-load and dump on you. They pump these sub $1 biotechs with flow floats. You will destroy your account. They are not qualified to talk biotechs. They will make up random catalysts to tempt you. Be smart with your hard earned money. When I call out a ticker it will be a medium to long swing. It takes weeks for me to get a full position. Chances are your average will be lower than mine. Many of my tickers will have multiple catalysts and can take months to a couple of years to play out. Also I may"
X Link 2024-02-10T17:20Z [----] followers, 10.7K engagements
"@FatManApe I see it heading back at least 3x where it is now because the momentum of their pipeline will accelerate. Also buyout possibilities as well. They basically will have a monopoly in TIL for several types of solid tumors"
X Link 2024-02-13T23:21Z [----] followers, [---] engagements
"$IOVA- Latest 13Gs show institutions like Vanguard Blackrock and others added more than [--] million shares. You think they know whats coming"
X Link 2024-02-14T04:51Z [----] followers, [----] engagements
"In the spirit of following the science I took a position in $LUNR. I have traded this ticker several times. Its at near absolute bottom. They have a launch tonight at 1:05 am EST. They have contracts with NASA to bring scientific instruments to conduct various tests. I will provide more DD later. On 2/22/2023 share price went up to $136. It wont go that high but if they successfully landed on the moon. You know where the price will be Watch the launch live tonight"
X Link 2024-02-15T00:42Z [----] followers, [----] engagements
"$LUNR - As humans have aspirations to explore deeper into space and beyond Intuitive Machines will be in the thick of it all. The company if successful with its lander being carried by SpaceX Falcon [--] tonight its market cap will be in billions again. It all starts tonight"
X Link 2024-02-15T01:04Z [----] followers, [----] engagements
"$LUNR - Launch time is 12:20 am EST"
X Link 2024-02-15T03:11Z [----] followers, [----] engagements
"$LUNR LIVE broadcast of launch"
X Link 2024-02-15T05:23Z [----] followers, [----] engagements
"$LUNR - Loving the journey to the moon in every sense of the word. 🚀"
X Link 2024-02-15T14:57Z [----] followers, [---] engagements
"@garyhead70 Probably not. They will negotiate of course"
X Link 2024-02-16T22:20Z [----] followers, [---] engagements
"@West0_Cap @KerrisdaleCap They were completely wrong in their report. I saw the 20% drop and was hoping the Chief Scientific Officer of $ALT would counter but nothing. Heartbreaking"
X Link 2024-02-19T00:43Z [----] followers, [---] engagements
"$ALT -Did you know that I also spent months researching $ALT I almost picked $ALT over $VKTX. I think for now I chose wisely. However if you have invested in $ALT I believe the phase [--] will not bomb like @KerrisdaleCap wrongly predicted (for selfish reasons). I believe $ALT phase [--] results will be great"
X Link 2024-02-19T01:06Z [----] followers, [----] engagements
"$ALT - Please listen to me - Nausea vomiting and diarrhea are the [--] most common adverse events and mainly mild to moderate and occur mostly in the first [--] weeks. Did you know that there is a drug on the market right now that can produce projectile vomiting Its Trulicity. Its the once weekly GLP-1 that belongs to drum roll please- Eli Lilly. Its making billions. The three adverse events are universally acknowledged and accepted. If you take these drugs and experience no nausea it is not going to work. But doctors know how to manage nausea. THE BENEFITS OUTWEIGH SIDE EFFECTS. And the side"
X Link 2024-02-19T02:18Z [----] followers, [----] engagements
"$ALT @KerrisdaleCap pemvidutide didnt do much for glucose control. This is the same mistake the last idiot wrote about $ALT (coincidence) from Seeking Alpha. Free lesson here. This is an obesity not diabetes trial. So the glucose level must be outside of the diabetic range. Thats why the baseline is [---]. If pemvidutide lowered glucose in this trial patients would have gone hypo and possibly died"
X Link 2024-02-19T02:37Z [----] followers, [----] engagements
"Folks we are a long way away from obesity being a crowded market. $VKTX $NVO $LLY $ALT are not competing against each other yet. Obesity is a big (pun intended) market. They are competing against a costly disease- obesity"
X Link 2024-02-19T02:50Z [----] followers, [----] engagements
"$ALT $VKTX The point I am trying to get across is this: [--]. Obesity is a worldwide problem [--]. Obesity and its consequences overburden the worlds healthcare systems. [--]. We need better treatments to fight diabetes and obesity. [--]. We still dont know what combination will work best yet even though there are at least [--] different combinations coming out including gene manipulation. [--]. We still need more drugs to combat [--]. THE MARKET IS NOT CROWDED YET [--]. No companies is trying to overthrow $LLY and $NVO please stop using this ridiculous argument. [--]. We should cheer for companies to succeed. The more"
X Link 2024-02-19T06:15Z [----] followers, [----] engagements
"You should be wary of a person defending a ticker that he or she is not in. What the heck is integrity doing on social media Be wary of someone that stands up for something on social media. Its really strange. $ALT must be the ticker I am heavily in since I am spending so much time defending it right I dont have any $ALT shares. I will not invest in $ALT. Not because it will fail but its because I like $VKTX better based on my qualifications. Yes Jim. Dont trust anyone including me"
X Link 2024-02-19T06:36Z [----] followers, [--] engagements
"@fluffer9 😂 You afraid of $ALT You know $VKTX are going for the same diseases right Obesity and NASH. So when I looked into the hot market for obesity you would think its natural for me to look at both of them right"
X Link 2024-02-19T06:43Z [----] followers, [---] engagements
"@fluffer9 $VKTX You know I almost blocked you because I thought you were trying to bash $VKTX a while back when you asked me about patents issues with the drugs that VKTX owns. Now youre accusing me of selling $VKTX for $ALT Really 😂"
X Link 2024-02-19T06:49Z [----] followers, [----] engagements
"You know $ALT and $VKTX are both dual agonists right They target different receptors. I already mentioned $LlY is coming out with the triple agonist and is showing effectiveness. The reason I invested in $VKTX and not $ALT is because it is less risky thanks to Mounjaro and Zepbound. The bottom line is we dont know how $ALT will turn out. I just happen to think it will be fine. The thing that got me started on this was Krissdale said the drug did nothing for glucose control"
X Link 2024-02-19T13:16Z [----] followers, [----] engagements
"@fluffer9 Im not allowed to sell some of my $VKTX shares Im not allowed to invest in anything else Dont forget I got into $LUNR too. This is ridiculous. Im not allowed to tweet about anything else other than $VKTX"
X Link 2024-02-19T13:20Z [----] followers, [---] engagements
"$IOVA $LUNR $VKTX Tuesday 🚀"
X Link 2024-02-19T13:35Z [----] followers, [----] engagements
"$LUNR - rooting for advancement of humanity in space. $IOVA - Rooting for fewer funerals because of cancer. Its more than just money. But gladly accept the opportunity that investing provides"
X Link 2024-02-19T14:39Z [----] followers, [----] engagements
"$IOVA- Think long term on this one. That is why its in my IRA account. This approval as I mentioned previously is just a stepping stone. The next big catalyst and I would argue is the biggest in the companys history is TILVANCE [---] confirmatory trial. Oh the buyout target on its back is getting bigger by the day. Patience"
X Link 2024-02-20T14:42Z [----] followers, [----] engagements
"$LUNR - we are heading to the moon in every sense of the word"
X Link 2024-02-20T15:25Z [----] followers, [----] engagements
"$IOVA- Investors on offering:"
X Link 2024-02-20T17:06Z [----] followers, [----] engagements
"The most profitable way to trade biotech is through catalysts and getting in early. After identifying a solid company that checks out using my qualifications the risks are much much lower and you dont even have to hold through the catalysts $VKTX is a great example We are still waiting on catalysts"
X Link 2024-02-21T03:14Z [----] followers, [----] engagements
"$AQST- Anaphylm will change the treatment paradigm for severe allergic reactions and anaphylaxis. Study after study show that people are not carrying the EpiPen and Audi-Q with them. The medication may be damaged. Not with Anaphylm. Its heat freez crash ( run over by a car and still undamaged. Say goodbye to the painful injections. Just put Anaphylm under the tongue without the need to swallow Game changer"
X Link 2024-02-22T15:09Z [----] followers, [----] engagements
"$AQST - watch this to meet the management team. CEO is very sharp"
X Link 2024-02-22T15:14Z [----] followers, [----] engagements
"$AQST - Anaphylm (Sublingual Epinephrine) doesnt just matched the efficacy and safety of EpiPen (Pfizer) and Audi-Q (Sanofi) it outperforms them. Drug concentration is similar or better but what makes Anaphylm shine is the Mean Arterial Pressure (MAP). EpiPen and Audi-Q do not maintain MAP and consequently patients will faint due to low blood pressure and decreasing blood flow to vital organs. On the other hand Anaphylm seems to do that very well"
X Link 2024-02-22T15:40Z [----] followers, [----] engagements
"@georgedemirakos I have trimmed both of my positions to make room for $AQST. But I still have a nice chunk in my portfolio for $VKTX $IOVA $ARQT and $FUSN. I am out of $LUNR"
X Link 2024-02-22T15:56Z [----] followers, [----] engagements
"$AQST - Today ARS Pharma $SPRY announced positive top line data that addresses the CRL (Complete Response Letter) from the FDA. More like a rejection letter but in this situation it was not that severe. As I mentioned before not all CRL are catastrophic Sometimes the FDA just says hey do this too in a trial so we can make sure your drug is safe. Unfortunately most uninformed investors panic and lose their shares and money. $SPRY shares tanked on that news several months back. Glad they got positive results. This situation TOTALLY benefited $AQST because they went ahead and added the REPEATED"
X Link 2024-02-22T18:49Z [----] followers, [----] engagements
"$LUNR - my second favorite hobby - astrophysics. Loving every minute of the launch and landing. Go"
X Link 2024-02-23T03:26Z [----] followers, [----] engagements
"$LUNR - Odysseus is on its side but it seems like they still will be able to execute most of the goals of the scientific payloads. Biggest issue they mentioned is the antennas are pointing forward towards the moon so that communication with Odysseus may be a challenge. They said this event taught them a lot for future missions especially with the navigation lidar system. They will have compliment systems so that when [--] failed the other will compensate. The biggest problem with this mission was the lazer on the lidar that supposed to give depth perception didnt work. They will get it right."
X Link 2024-02-24T14:22Z [----] followers, [---] engagements
"$AQST - Since it is really time consuming when doing thorough research on a company that I am interested in one of the first things that I look at is the market cap and what I can potentially gained in short medium and long term if I choose to go long. Then I look at the products the company is making. At this point Im asking myself what is the total addressable market (TAM) for the products. Usually there are multiple products or drugs but there is usually the main one that I will focus on. My minimum potential gain for each company that I decide to invest in is at least 3X from my entry"
X Link 2024-02-24T19:30Z [----] followers, [---] engagements
"No. $2.5 billion is more realistic. I believe a $2.5- $3 billion buyout is very possible and likely. Pfizer is having nightmares. Kaleo too. Plus all of the generic auto injectors manufacturers. Poof. Gone. The moment $AQST Anaphylm appears on the market it will dominate because of UNMATCHED CONVENIENCE"
X Link 2024-02-25T04:21Z [----] followers, [---] engagements
"$AQST - As promised I am going to share with you a huge nugget that none has even given it a second thought when they saw it. In my qualifications #5 (Incremental success through various stages of clinical trials) is critical when deciding whether to invest in a certain biotech company. Why There is usually [--] very big drug that they are working on and the future pretty much depends on it. $IOVA - Its the trials for Amtagvy. Got approval because all the smaller trials prior to the pivotal phase [--] trial showed positive results. $VKTX will be the same with VK2809 VENTURE. Please get to the"
X Link 2024-02-26T04:09Z [----] followers, [----] engagements
"$ALT - Not in it but I did place a challenge to a debate that their short report was bogus. Written by a high school student with wrong conclusions. Love seeing them getting destroyed"
X Link 2024-02-26T13:34Z [----] followers, [----] engagements
"$AQST - Remember they dont just have drugs. They have a platform The CEO already talked about all of the possibilities of in and out licensing products for other companies. The possibility is massive. Read the company profile. Its all in there. They are very experienced in drug manufacturing"
X Link 2024-02-26T17:13Z [----] followers, [---] engagements
"$AQST - In medicine one of the biggest problems is DEVICE FAILURE. Most of the failures is due to incorrect usage or administration. Let me list the devices to treat severe allergic reactions and anaphylaxis: [--]. Manual Injection [--]. EpiPen (Mylan Pharmaceuticals owned by $PFE [--]. Auvi-Q (Kaleo Pharma). [--]. Neffy by $SPRY Let me list non-device treatments for severe allergic reactions and anaphylaxis [--]. Anaphylm by $AQST is the first and only non-device sublingual film to treat severe allergic reactions and anaphylaxis. So easy you know the rest"
X Link 2024-02-26T23:33Z [----] followers, [----] engagements
"$AQST - Anaphylm entering the market. You know what happens to its competitors💀"
X Link 2024-02-27T01:23Z [----] followers, [----] engagements
"$VKTX - I should definitely think about opening a psychic hotline. They got 14% and placebo adj 13%. Shorts will be destroyed. I also predicted a buyout. Thats next. $VKTX - Subq phase [--] VK2735 VENTURE trial if they get 15-17% weight reductions in just [--] weeks including titration the shorts will absolutely be destroyed. I think this is very achievable or exceeded btw. $VKTX - Subq phase [--] VK2735 VENTURE trial if they get 15-17% weight reductions in just [--] weeks including titration the shorts will absolutely be destroyed. I think this is very achievable or exceeded btw"
X Link 2024-02-27T12:24Z [----] followers, [----] engagements
"@jfmcrr They dont have anything on the market. In VK2735 a dual receptor agonist of GLP-1/GIP is the same combination as $LLY Mounjaro and Zepbound (Tirzepatide) and those drugs are amazing. $VKTX"
X Link 2024-02-27T16:09Z [----] followers, [---] engagements
"@HFK23x It depends on your risk tolerance. But never go all in for [--] ticker brother"
X Link 2024-02-27T16:58Z [----] followers, [---] engagements
"Much much higher. Look at 9/2018. It got to $20.70 with nothing basically. Thats several months after IPO. Now with $50 mil revenue [--] drugs on the market though very small size and [--] big ones coming. The biggest being Anaphylm. First ever non-device convenient treatment for severe allergic reactions and anaphylaxis. Then Libervant for seizures using the same film delivery system. Game changer for both"
X Link 2024-02-27T18:20Z [----] followers, [---] engagements
"$AQST - Pfizer Kaleo and ARS just got the news that Anaphylm will be coming to market. Their reaction:"
X Link 2024-02-27T20:03Z [----] followers, [----] engagements
"$VKTX - Offering"
X Link 2024-02-27T21:22Z [----] followers, [----] engagements
"$VKTX - If no buyout then I am going to apply for a VP of sales and marketing position. No chance. Buyout is 100% going to happen"
X Link 2024-02-27T21:41Z [----] followers, [----] engagements
"$AQST - You will see the cash burn rate is not that much. This company is very well run and pretty lean. The biggest cost for a startup biotech is clinical trials. Each trials can cost $100 mil or more. Not with $AQST. These trials are very different from typical trials where you enroll sick patients; getting them stablized on standard of care drugs then a wash out period etc again very time consuming and expensive. Take the trials for $VKTX for example. The offering today was for you guessed it- more trials. For $AQST remember they cant make people get to anaphylaxis. Thats unethical and not"
X Link 2024-02-28T05:19Z [----] followers, [----] engagements
"$AQST - I keep getting questions about their financials. Yes they have only $24 mil. But they are generating revenue unlike MANY of their biotech counterparts. Is there a chance of an offering Yes but their operations are not cash intensive like many others due to the low cost clinical trials. Even if they do an offering it probably to launch their products wouldnt you mind that After all you invested in a biotech to see them bringing products to the market to generate wealth and help patients right How did investors react to $VKTX offering yesterday $350 million VKTXs previous offering was"
X Link 2024-02-28T12:28Z [----] followers, [----] engagements
"Today we are going to talk about CONTEXT. You are following me so I am assuming that you are interested in investing in biotechs. To summarize what I do here is I find biotech companies and do thorough due diligence on them. I look at everything but especially their pipeline and determine if a company is worth my time and money. I dont like to lose so the companies have to pass a rigorous evaluation process before I pick them. I pinned the qualifications that I check off for each ticker. I encourage you to do the same. Now back to CONTEXT. You have to look at things in a bigger picture to put"
X Link 2024-02-28T14:20Z [----] followers, [----] engagements
"It will be a while before I release the next company that found that also has a PLATFORM. You will absolutely love this one. DD has been 75% done. What sector The white hot OBESITY. Has to be unique and game changing to be chosen. This one got it. Stay tuned dragons 🐉 (thats our mascot). Just came up with that. Hope you all approve Thoughts"
X Link 2024-02-28T14:42Z [----] followers, [----] engagements
"$IOVA $AQST I talked about context earlier. In the case of $AQST its financials. In $IOVA- If you look at their ORR (Objective Response Rate) of 39%. its pretty low in their pivotal trial that got them FDA approval for Amtagvi. HOWEVER These are the patients who are very sick and already talking to funeral planners. These patients have months some weeks or days. So you cant expect an ORR of 50% like with other forms of cancer. Context is so important. A huge part of data analysis"
X Link 2024-02-28T15:50Z [----] followers, [----] engagements
"$AQST Just so you understand. The potential I see in this company is the same as $VKTX if you look at market cap. I called $VKTX at $12. I saw 10X potential. Same with $AQST. I am an investor. If you are a flipper you may get frustrated with my tickers. If you dont notice by now I love gaming changing technology in a company. $AQST has EXACTLY that"
X Link 2024-02-28T15:58Z [----] followers, [----] engagements
"@sgonza33 More unknowns vs $VKTX thats all. I like $ALT but not enough to invest"
X Link 2024-02-28T16:00Z [----] followers, [---] engagements
"$AQST - Catalysts and timelines: [--]. 3/5/2024 - Earnings via PR- AH [--]. 3/6/2024 - Earnings call [--] am EST. [--]. By end of March Ph3 data release [--]. 4/28/2024 - PDUFA Libervant age 2-5. [--]. TBD - Announcement of partnership to launch pediatric Libervant [--]. TBD Start pediatric trial for Anaphylm [--]. Apply for NDA for Anaphylm by end of [----] [--]. PDUFA for Anaphylm - 2H [----] [--]. Launch Anaphylm - 2H [----] [--]. 1/11/2027 - Launch Libervant for adults [--] and up. [--]. If you are still in $AQST and I hope you will be congrats"
X Link 2024-02-28T21:05Z [----] followers, [----] engagements
"@ben_siravo @Mark748779211 Thanks for the great questions. [--]. Not bad for $LLY at all. Market potential is not reached. Still plenty of room for these drugs to coexist. [--]. $PFE and $BMY Then $AZN top [--] possible buyers"
X Link 2024-02-28T21:10Z [----] followers, [---] engagements
"Those [--] were picked because Pfizer tried to get in the Obesity market but failed with their compound. They have money to get the drug from VKTX. BMY. They have shown interest in Obesity as well. AZN brought the first GLP-1 to market with Byetta $AQST - PharmFilm technology was developed in house. Yes they can out license. That information is also on their website. This company has so much going for it. Thanks for the questions"
X Link 2024-02-28T21:47Z [----] followers, [---] engagements
"$AQST - Headquarters is in New Jersey. Massive pharmaceutical industry hub. Johnson and Johnson Merck Bristol Myers Squibb Novo Nordisk to name a few. Pfizer is close by in New York. These big boys will start noticing $AQST soon"
X Link 2024-02-28T23:07Z [----] followers, [----] engagements
"$VKTX - Never thought I would say this but I thought dilution risk for $VKTX is low but damn man Should I tell them to take a good look at $AQST EVERYONE should look at $AQST regardless. Upside is similar to $VKTX when it was $12"
X Link 2024-02-29T02:37Z [----] followers, [----] engagements
"$AQST - On July [--] [----] Aquestive Therapeutics introduced itself to the market on IPO day. Their quest: Advancing medicines Solving therapeutics problems Improving lives Less than [--] months later the share price shot up to $20.70 with only a dream. Here it is more than [--] years later it has the opportunity to prove imto the world that Anaphylm can save lives for patients suffering from severe allergic reactions and anaphylaxis in a phase [--] readout coming anytime in March. The magnitude of this topline data cannot be overstated. Even the CEO Dan Barber said on the Oppenheimer Science conference"
X Link 2024-02-29T18:55Z [----] followers, [----] engagements
"$AQST - dips will come but not many as we get closer to catalysts. [--]. Earnings 3/5 then the call on 3/6. After that a BIG one phase [--] data readout sometime in March. Could be same day as earnings call"
X Link 2024-02-29T20:20Z [----] followers, [----] engagements
"$AQST - Soon you will see it all over the news about the newest treatment option for severe allergic reactions and anaphylaxis and you can talk back to the TV or your smart phone. Yes I know this company. And I proudly own a piece of that company"
X Link 2024-02-29T20:42Z [----] followers, [----] engagements
"@rkpm33tang @georgedemirakos @wangruntu1988 Yes I do. $AZN is focusing on oncology quite a bit. $IOVA is in a great place with or without a buyout"
X Link 2024-02-29T21:27Z [----] followers, [---] engagements
"@deacon451 Nope. They are way behind $AQST and they still will have to wait until [----]. The ODE affects everyone. $AQST already got tentative approval. Jan [--] [----] is launch date"
X Link 2024-02-29T22:06Z [----] followers, [---] engagements
"$AQST - This company has experience. I really like the CEO Daniel Barber. He understands the sales and marketing side of the business really well. Another peace of mind for me because thats what I do"
X Link 2024-02-29T22:56Z [----] followers, [----] engagements
"@lovejklmn Not even close. Hot cold run over by a car and still be ok. Fits in a smartphone case. Thinner than a credit card. $AQST"
X Link 2024-03-01T21:59Z [----] followers, [---] engagements
"@TheRealDanSfera Lots. Go back and check out my previous posts"
X Link 2024-03-02T15:44Z [----] followers, [---] engagements
"$AQST - $SPRY $836 mil market cap to be exact. $283mil for $AQST. Yes its a shocker. @BIOTECHSCANNER Market cap of $283 is a shocker considering that the next closest innovator within this indication (ARS pharma) has a market cap of $700+. Stocks slept on. My question being is their strategy to out-license this product or commercially launch it themselves @BIOTECHSCANNER Market cap of $283 is a shocker considering that the next closest innovator within this indication (ARS pharma) has a market cap of $700+. Stocks slept on. My question being is their strategy to out-license this product or"
X Link 2024-03-03T00:44Z [----] followers, [----] engagements
"Welcome my new friends from South Korea. I had a privilege of working with International students from Japan South Korea Mainland China Hong Kong and Vietnam when I was a Director of International Student Recruitment at a university before I entered the pharmaceutical industry. I made many friends and still keep in contact with several. My wife wants to visit Japan this summer. We go to Seoul Korea but only inside Incheon Airport. Someday I want to visit South Korea too Thank you for spreading the good news about $AQST and Anaphylm"
X Link 2024-03-04T03:06Z [----] followers, [----] engagements
"@AethernCapital Thank you for your kind words. My followers including you deserve the best. Our livelihood depends on it"
X Link 2024-03-04T11:44Z [----] followers, [---] engagements
"@dvdbeaver1 My buyout price for $AQST is least $1.5B. Remember they have a platform in PharmFilm and drug permeation enhancement technology. The possibilities are endless. They also have a strong drug manufacturing experience as well"
X Link 2024-03-04T13:20Z [----] followers, [---] engagements
"There are companies that make lap bands for weight loss that you can invest in. I HIGHLY RECOMMEND NOT TO Why do you think that is Have you heard about a class of drugs called GLP-1 Cmon friends. Be smart. Respect your money. Our families depend on it. Be wise"
X Link 2024-03-04T14:00Z [----] followers, [----] engagements
"$AQST - Look at the previous analysis I have done especially on $VKTX $ARQT $CALT $IONS and $IOVA on approvals and data release. I know biotech analysis. That I know. $AQST at this level is a gift"
X Link 2024-03-04T19:04Z [----] followers, [----] engagements
"This right here is a big reason why you dont have more people devoted their time for the good of the investment community. Yes I am reconsidering doing this. People are so ungrateful. @BIOTECHSCANNER Why are you pumping so much @BIOTECHSCANNER Why are you pumping so much"
X Link 2024-03-05T03:50Z [----] followers, [----] engagements
"@pharmdaz I am a Dallas Mavericks fan. Please stop 😂. We got our revenge though"
X Link 2024-03-05T21:36Z [----] followers, [---] engagements
"@SexyStockSlayer Thats interesting. Thats wrong though as far as I know"
X Link 2024-03-05T21:41Z [----] followers, [---] engagements
"$AQST - We remain excited to see our topline pivotal data and continue to anticipate reporting topline data from our Anaphylm pivotal study this month. Highly recommend shorts to google Goodwill near me soon"
X Link 2024-03-06T06:07Z [----] followers, [----] engagements
"$PFE is a perfect company to buy $AQST. They have the sales force in the US and International. They have experienced selling epinephrine. An absolute perfect fit"
X Link 2024-03-06T14:08Z [----] followers, [----] engagements
"@MartyChargin They are too cheap for $VKTX because they waited for VENTURE results to come out. Now its too expensive. The more you look the more you pay. Thats how it works in biotech buyouts. They definitely can afford $AQST. Thats a drop in the bucket for them. $1.5 billion"
X Link 2024-03-06T14:15Z [----] followers, [---] engagements
"$AQST - You all heard from the management personally. I am very excited about the future of the company. The difference between others my myself is I make it known. I dont need to pump. I dont tell people to buy or to sell. I provide education when theres an unmet need in this community. Unfortunately there are some crazy folks on this platform who are mostly likely shorts. The biggest comfort factors that shorts have in their favor are [--]. Lack of information within the investment community. [--]. They play with investors fears. And without proper information investors are helpless. I am not"
X Link 2024-03-06T14:26Z [----] followers, [----] engagements
"$AQST - After a great earnings call and a huge phase [--] topline data coming in [--] weeks. People are losing precious shares"
X Link 2024-03-06T14:40Z [----] followers, [----] engagements
"$AQST - New analyst rating of a BUY and $8 PT. Hmm Who lost shares this morning"
X Link 2024-03-06T16:28Z [----] followers, [----] engagements
"$AQST- Not satisfied yet. Not even close. My conviction for this is the same as $VKTX. Patience. Amazing things happening here at $AQST. By the way they did use the words transformative and transformation on the earnings call"
X Link 2024-03-06T20:46Z [----] followers, [----] engagements
"$VKTX $NVO The news today on amycretin weight loss. This data was sent to Novo Nordisk employees via email [--] years ago. No I didnt buy any $NVO shares after receiving the email. Shoulda 😂. Was trading at $30 levels"
X Link 2024-03-07T14:54Z [----] followers, [----] engagements
"Please stop bashing $VKTX and $NVO. $LLY is a great company and amazing products. So as $NVO. I have friends at $NVO and $LLY. When I was at Novo we have the utmost respect for $LLY and vice versa. The market is massive for diabetes and obesity. This is not a zero sum game. The market can use [--] or more drugs to address these problems that cost society trillions and more coming. Personally I am rooting for all of them to succeed. The drop in prices for $VKTX and $LLY is unwarranted especially for $LLY. The more options physicians have the better because some patients may not tolerate one drug"
X Link 2024-03-07T15:51Z [----] followers, [---] engagements
"@Anders_Research @TheRealDanSfera I have not compared efficacy between the two because they have not been tested against each other. I only pointed out Anaphylm is more convenient"
X Link 2024-03-08T00:16Z [----] followers, [---] engagements
"@farazsid47 We have to wait until the company officially releases their data. That is the fairest way to treat the company. Let the data do the talking. I have my gut feelings about the oral VK2735. I am going to hold it"
X Link 2024-03-08T05:37Z [----] followers, [---] engagements
"The environment in the stomach is very acidic. The company has to put some type of coating around the peptide in this case VK2735 to protect it from acid destroying the GLP-1 before getting absorbed. $NVO has a technology for that with an absorption enhancer sodium N- (8- 2- hydroxybenzoyl amino) caprylate (SNAC) which facilitates the absorption of semaglutide across the gastric epithelium in a concentration dependent manner"
X Link 2024-03-08T13:08Z [----] followers, [---] engagements
"$AQST - Thanks for the follow. Heres the recording of the latest earnings call on March [--]. The CEO said worldwide Anaphylm sales can see surpass $1 billion per year. Libervant for 2-5 year old between $100-$200 million. This number will be higher when Libervant for adults is launched in January of [----]. Finally AQST [----] the cream for dermatology can get multi hundred million per year. Now look at the current market cap. This company is very under valued. Thanks for listening to the Oppenheimer conference. Please listen to this webcast for the latest updates"
X Link 2024-03-10T00:11Z [----] followers, [---] engagements
"@meputzke20 They probably dont have it yet. I am more confident today than when I first invested it $AQST especially after the earnings call. I think the management is to make a big splash on data day"
X Link 2024-03-10T03:46Z [----] followers, [---] engagements
"@TomHamil3 @meputzke20 Data day is not set. CEO said in [--] weeks on the earnings call on 3/6. If it is exactly [--] weeks then its on 3/20. $AQST"
X Link 2024-03-10T11:34Z [----] followers, [---] engagements
"@down_dogdiv For which ticker For $AQST it will probably be in billions by [----]. Please listen to the latest earnings call on 3/6/2024"
X Link 2024-03-10T16:46Z [----] followers, [---] engagements
"$AQST - I will write up what to expect from Phase [--] next weekend as we anticipate possible data release on 3/20 which is [--] weeks from the earnings call. On the call CEO Dan Barber said talk to you in [--] weeks. I cant tell you all how excited I am for this"
X Link 2024-03-11T05:38Z [----] followers, [----] engagements
"$AQST - CEO Dan Barber who is a very conservative person who is very deliberate with his statements because he knows the FDA is watching everything he says on Anaphylm. On 3/6/2024 during the earnings call he confidently stated that he expects global sales of Anaphylm once approved will exceed $1 billion. Libervant for 2-5 year olds (could launch this summer) $100-$200 million. These are only [--] main asset (Anaphylm) and a fraction of the other asset (Libervant for adults). Also the cream isnt counted yet. I understand the pharmaceutical industry market well because this is what I do. I can"
X Link 2024-03-11T14:25Z [----] followers, [----] engagements
"@Fire_Truck5 Market cap for $AQST is ridiculously low"
X Link 2024-03-11T15:38Z [----] followers, [---] engagements
"$AQST - Heres another prediction I made before the PDUFA date for $IONS. Again using my experience to analyze clinical trials and medication to the molecular level. This is part [--] of my prediction series"
X Link 2024-03-12T13:34Z [----] followers, [----] engagements
"@Liftthatbid @pharmdaz Much better upside with $AQST. SPRY [--] product. No rev. $AQST - [--] already generating $50.6 mil. Go to their websites. I have no doubt you will like $AQST more. The market cap is ridiculous low vs spry"
X Link 2024-03-12T14:47Z [----] followers, [---] engagements
"Yes. This is true. I saw this when I looked into SPRY. Still it doesnt change my risk assessment between the two. I still personally see a much better upside for $AQST. I look further ahead of what will be the preferred option and it will always be Anaphylm. Even if Neffy comes to market first. The moment Anaphylm arrives its over. Look at [--] diabetic drug call Invokana in the class of diabetes drugs called SGLT-2 inhibitors. It was first in class. First to market. Janssen doesnt even promote it anymore. Farxiga made it to the top [--] list that I shared yesterday. The market will sort it out"
X Link 2024-03-12T21:23Z [----] followers, [---] engagements
"$AQST- This is the Q4 earnings call on 3/6/2024. Please take a listen if you have not. Listening to this will get you caught up on the past present and future of the company. Its an exciting time to be investors in Aquestive Therapeutics for sure"
X Link 2024-03-13T18:11Z [----] followers, [----] engagements
"@gkrisrao @Anders_Research @Jonny_fun_guy They will do whatever is best for the company. They know much more than we do. I am very impressed with them. I wouldnt do an offering at this price. No way. I can tell they really like to keep the share structure lean for an especially if they want a buyout"
X Link 2024-03-15T22:41Z [----] followers, [---] engagements
"@OmerLandau1 @J313Ya CEO was talking about the 2-5 year olds sales potential. Remember he was saying globally. Notice he was saying launch as early as this year"
X Link 2024-03-16T21:37Z [----] followers, [---] engagements
"$FUSN - Family on 12/27/2023 I said $FUSN would be bought out by $AZN. Congrats to all Today: $FUSN - hitting [--] wk highs but dont let that scare you. This is a MAJOR buyout target. They have some of the best cancer assets on the market. I believe they will get bought out by $AZN at some point in $3-5 billion range. https://t.co/mzEI1LNAQ5 $FUSN - hitting [--] wk highs but dont let that scare you. This is a MAJOR buyout target. They have some of the best cancer assets on the market. I believe they will get bought out by $AZN at some point in $3-5 billion range. https://t.co/mzEI1LNAQ5"
X Link 2024-03-19T11:16Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing